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ABSTRACT 
THE ROLE OF FYN AND B-CELL EXPRESSED ADAM10 IN EARLY B CELL 
DEVELOPMENT, GERMINAL CENTER FORMATION AND TERMINAL B CELL 
DIFFERENTIATION 
 
By Natalia Sol Chaimowitz, Ph.D. 
 
A dissertation submitted in partial fulfillment of the requirement for the degree of 
Doctor of Philosophy of Virginia Commonwealth University 
 
Virginia Commonwealth University, 2012 
 
Director: Daniel H. Conrad, Professor, Department of Microbiology and 
Immunology 
 
 In these studies we sought to determine the role of Fyn kinase and 
ADAM10 in B cell biology. A disintegrin and metalloproteinase 10 (ADAM10) is a 
zinc dependent proteinase related to matrix metalloproteinases. ADAM10 has 
emerged as a key regulator of cellular processes by cleaving and shedding 
extracellular domains of multiple transmembrane receptors and ligands. In 
particular, ADAM10 has been identified as a key regulator of lymphocyte 
development. Here we report that ADAM10 is dispensable for early B cell 
development within the bone marrow. However, deletion of ADAM10 from all 
peripheral B cells or in post-switch cells leads to severe impairments in humoral 
responses. When ADAM10 was deleted from all peripheral B cells a decrease in 
antigen specific IgG production was seen both with respect to serum levels and 
IgG ASCs, indicating that plasma cell (PC) differentiation is influenced. Cells 
producing high affinity antigen specific antibodies were particularly affected, 
consistent with defects in germinal center (GC) reactions. Moreover, changes in 
 xix 
lymphoid architecture were also observed. Consistent with these findings, 
follicular dendritic cell (FDC)-reticula was undetectable following immunization. 
On the other hand, when ADAM10 was deleted in post-switch B cells, GC 
formation and lymphoid architecture were not impaired. Despite normal 
architecture, however, antibody production was still affected, likely due to 
abnormal gene expression in ADAM10-deficient PCs. Consistent with this 
hypothesis, PCs isolated from ADAM10Δ/ΔIgG1-cre+/- showed decreased 
expression of genes that facilitate plasma cell differentiation and function and 
increased expression of Bcl6, an inhibitor of PC differentiation.  
 Fyn kinase is a member of the Src protein tyrosine kinase. Fyn is widely 
expressed in many cell types, including lymphocytes. Fyn has been shown to 
interact with both the B cell and T cell receptor (BCR and TCR, respectively). 
While Fyn-deletion did not impair the development of immature T cells and B 
cells, TCR signaling was altered in mature T cells. Our results demonstrate that 
Fyn-KO mice have significantly low basal levels of IgG1 and IgG2a. Additionally, 
these mice displayed delayed kinetics in the production of NP-specific IgG1 and 
IgG2b, and significantly low NP-specific IgG2a after a T-dependent immunization 
protocol. Defects in antibody production correlated with significantly reduced 
numbers of GC B cells, TFH cells and splenic PCs. Moreover, Fyn-KO B cells 
showed decreased production antibody following in vitro activation. Our results 
thus demonstrate that Fyn-mediated signaling and B cell ADAM10 expression 
are necessary for optimal humoral responses. 
 
 1 
CHAPTER 1: INTRODUCTION TO B CELL DEVELOPMENT AND TERMINAL 
DIFFERENTIATION 
 
 B-lymphocytes (B cells) are the key mediators of humoral immunity. There 
are two main populations, referred to as B-1 and B-2 cells. B-1 cells are a minor 
subpopulation of B cells commonly found in peritoneal and pleural cavities and 
are mediators of innate immunity. B-2 B cells, on the other hand, are the 
predominant B cell population and can be found in spleen and lymph nodes (LN). 
Here we will discuss B-2 cells. B-1 B cell development and function is reviewed 
elsewhere1. 
 B-2 cell development can be divided into several stages. The different 
stages of B cell development are depicted in Figure 1 and will be further 
described here.  
  
 2 
Figure 1. B cell development and differentiation.  
B cell development is initiated within the bone marrow (BM). Common lymphoid 
progenitor cells (CLPs) commit to a B-cell pathway. Pro- and pre- B cells 
undergo a series of steps in order to generate cells that express a functional 
surface IgM. Once surface IgM is expressed, immature B cells exit the BM and 
home to secondary lymphoid tissues, such as lymph nodes and spleen, where 
they are considered mature B cells. Upon antigen activation, B cells proliferate 
and differentiate. B cells can rapidly differentiate into PCs; these cells typically 
secrete IgM and are short-lived. Activated B cells can also enter germinal 
centers, where they undergo somatic hypermutation (SHM) and class switch 
recombination (CSR). Cells that have low affinity for antigen undergo apoptosis, 
while those B cells that express high affinity for antigen are selected for survival 
and can further differentiate to memory B cells and PCs. Long-lived PCs typically 
home to the bone marrow, where they can remain for years.  
 3 
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1.1 Early B cell development  
 B cell development is initiated within primary lymphoid organs - the fetal 
liver during gestation and the bone marrow (BM) throughout the remainder of life. 
B cell development is carried out such that B cells with a diverse repertoire of 
antigen specificities are generated. This diversity is achieved by rearrangement 
of the immunoglobulin heavy-chain (IgH) and immunoglobulin light-chain (IgL) 
segments of the B-cell receptor (BCR) genes. Moreover, recombination events 
often lead to insertions or deletions in coding regions of immunoglobulin genes. 
This junctional diversity also contributes to the generation of cells with very 
varied antigen specificities. The recombination activating genes (RAGs) 
encode enzymes essential for the rearrangement and recombination of 
immunoglobulin genes. These enzymes are known as RAG-1 and RAG-22. 
These genes are also involved in T cell receptor (TCR) rearrangement, as 
described elsewhere3. The importance of these enzymes is highlighted by the 
fact that RAG-1 or RAG-2 deficiency causes severe combined immunodeficiency 
(SCID) due to a loss/absence of B cells and T cells4. 
 Gene rearrangement starts with recombination of the variable (V), 
diversity (D), and joining (J) gene segments of the IgH gene within pro-B cells, 
commonly termed VDJ rearrangement. The pre-BCR is then assembled. It is 
composed of the rearranged immunoglobulin M (IgM) heavy chain, a surrogate 
light chain, composed of VpreB and λ5, and accompanying signaling molecules. 
Productive IgM heavy-chain recombination leads to progression to the pre-B cell 
stage. The pre-BCR is a key checkpoint for the regulation of B cell development, 
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since pre-BCR expression and ligand-dependent signaling are prerequisites for 
further differentiation. Defects in the components of the pre-BCR or signaling 
molecules, such as Bruton’s tyrosine kinase (BTK), result in an early B cell 
developmental block5.  
 CD19, a B cell specific member of the immunoglobulin superfamily, is a 
co-receptor molecule that modulates pre-BCR and BCR signaling. CD19 is 
expressed starting at the pro-B cell stage. It has been proposed that CD19 
signaling is important for heavy-chain rearrangement by modulation of RAG-1 
and/or RAG-2 expression6. Moreover, it has been suggested that CD19 signaling 
can augment signals through the pre-BCR and aid in the transition from pro to 
pre-B cell stage7. Consistent with this idea, CD19-deficient mice have impaired 
B-cell proliferation at the pre-B cell stage8. Moreover, CD19 deficiency leads to 
decreased numbers of peripheral B cells. CD19+/- mice (heterozygous), however, 
had normal B cell development9. 
 Following heavy-chain rearrangement, rearrangement of the V and J 
segments of the light chain locus (either κ or λ) occurs. This rearrangement 
occurs at the pre-B cell stage. The light chain protein then associates with the 
previously rearranged and synthesized IgM heavy chain. Surface IgM expression 
marks the transition from pre-B cell to immature B cells. The immature, IgM-
expressing B cell then leaves the BM and completes its maturation, becoming a 
mature or naïve B cell, marked by the co-expression of IgM and IgD. Mature B 
cells home to secondary lymphoid organs due to their expression of CX 
chemokine receptor 5 (CXCR5) (see section 1.2)5. 
 6 
  
1.2 Secondary Tissue Structure 
 The development of secondary lymphoid tissues is initiated during 
embryogenesis by the interaction between hematopoietic lymphoid tissue inducer 
cells (LTi) and mesenchymal cells present at the sight of future lymphoid organ 
development. LTi cells express lymphotoxin αβ (LT) while mesenchymal cells 
express LTβ receptor. LT signaling is essential for the development of secondary 
lymphoid organs because it triggers mesenchymal cell differentiation to stromal 
organizer cells and induces homeostatic chemokine expression, such as 
CXCL13, CCL19, and CCL2110. Interaction of stromal organizer cells with LTi 
leads to the recruitment of additional hematopoietic cells and subsequent 
accumulation of naïve lymphocytes11.  
 Consistent with LT’s key role in lymphoid development, LT-deficient mice 
lack peripheral LN and have severely disrupted splenic architecture12,13. TNF-α 
deficient mice also have disrupted splenic architecture and abnormal lymph node 
follicle formation14. However, TNF-α involvement in lymphoid tissue development 
is poorly understood. It has been proposed that TNF-α is involved in the 
differentiation of stromal cells precursors into follicular dendritic cells (FDCs) and 
fibroblastic reticular cells (FRCs) (see section 3.3)15. 
 Secondary lymphoid organs are highly organized structure containing 
regions enriched for B cells or T cells. The segregation of B cell areas (follicles), 
and T cell areas (paracortex in lymph nodes and periarteriolar lymphoid sheath 
(PALS) in spleen) is dependent on specific chemokine secretion16,17. The 
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chemokine important for B cell homing is CXCL13. This chemokine is thought to 
be secreted by follicular dendritic cells (FDCs) within the follicles; its receptor, 
CXCR5 is constitutively expressed by follicular B cells18. CCL19 and CCL21 are 
secreted in T cell areas by fibroblastic reticular cells (FRC)19. Both of these 
chemokines are ligands for CCR7, a receptor expressed by naïve T cells and 
mature dendritic cells (DC) and are thus important for T cell homing and DC 
migration into lymphoid tissues16,20,21 . 
 Along with B cell and T cell regions, spleens also have a marginal zone 
(MZ), a structure that separates the lymphoid areas (white pulp) from the areas 
where arterial to venous exchange occurs (red pulp). The MZ surrounds the 
splenic follicles and it is made up of MZ macrophages and MZ B cells. MZ B cells 
are characterized by high expression of CD21, IgM, and CD1, as well as low IgD 
and CD23 expression22,23. Studies have demonstrated that MZ B cell 
development requires CD19, Notch2, and ADAM10 protein expression and 
signaling24-26.  
 Lymphocytes and DCs may enter LN from the blood by exiting the 
circulation via high endothelial venules (HEV) in the paracortex or through 
afferent lymphatics. Regardless of how they reach the tissue, B and T cells 
segregate according to their expressed chemokine receptors27. As mentioned 
earlier, the correct positioning of cells is dictated by the local production of 
chemokines by stromal cells as well as the coordinated expression of chemokine 
receptors by migrating cells18. The positioning of B cells and T cells, as well as 
their migration during an immune response, are critical for adequate B cell-T cells 
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interaction and for optimal immune responses28.  
 
1.3 B cell activation 
 There are several ways B cells can encounter antigen. B cells can acquire 
soluble antigen that diffuses freely into lymphoid follicles29 or that is transported 
through the lymphoid conduits system15. Moreover, B cells can be presented 
antigen by DC30  or subcapsular sinus macrophages27. B cells can respond to 
several kinds of antigens31. After challenges with most types of antigens, B cells 
rapidly differentiate into plasma cells (PCs) and plasmablasts and appear 
between red and white pulp in the spleen and the outer T-cell areas of the lymph 
nodes32. Extra-follicular responses are not thought to lead to the generation of 
long-lived PCs32. It should be noted that extra-follicular responses to T-
dependent antigens also require cognate T-cell help33. 
T-cell independent antigens 
 Certain antigens have the capacity to induce the differentiation of B cells 
into antibody-secreting cells (ASCs) in the absence of cognate T-cell help. These 
antigens are commonly referred as T-independent antigens and can be 
subdivided into two groups. Type-1 antigens can induce B cell proliferation and 
differentiation to ASCs independently of BCR signaling. LPS is the prototypical 
Type-1 antigen. Type 2 antigens, on the other hand, require signaling through 
BCR and are typified by polysaccharides from bacterial cell walls. Common Type 
2 antigens are haptens coupled to ficoll, dextran, or acrylamide. Type 2 antigens 
lead to BCR aggregation; moreover, they may activate non-B cells to produce 
 9 
cytokines and modulate the immune response31. 
 All B cell subsets can be recruited to extra-follicular responses to T-
independent antigens, although MZ B cells and B-1b cells are the only ones 
capable of responding to T-independent Type 2 antigens34. Low affinity IgM is the 
most common isotype seen in T-independent responses, although other isotypes 
can also be detected35. The process of class switching will be further described in 
Section 1.4. 
 
T-cell dependent antigens  
 Most antigens are T-dependent, meaning that T cell help is required for 
optimal antibody responses. Helper T cells aid in the activation of cognate B cells 
via cell-to-cell interactions (such as CD40 and CD40L) as well as through the 
release of cytokines that shape the B cell responses, such as IL-4 and IL-21. A 
hallmark of T-dependent antigens is that they are protein antigens. Like T-
independent antigens, they induce extra-follicular responses. Moreover, they also 
induce germinal center (GC) formation (see Section 1.4)36,37. 
  
1.4 Germinal Centers 
 GCs are structures observed in the follicular region of secondary lymphoid 
tissues. As mentioned earlier, GC formation is dependent on the interactions of 
cognate B cells and follicular helper T (TFH) cells and FDCs38. Within GCs, FDCs 
and TFH cells promote antigen-specific clonal expansion, class switch 
recombination (CSR) and somatic hypermutation (SHM) with selection of high 
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affinity BCR variants39. Clonal expansion refers to the rapid proliferation of 
antigen-specific B cells.  
  
Early responses to T-dependent antigens 
 Initial activation of naïve B cells through the BCR leads to increased 
expression of CC-chemokine receptor 7 (CCR7) and enhanced responsiveness 
to CD40L, thus promoting more effective cognate T cell help40. CCR7 expression 
allows B cells to migrate toward the T cell zone. Simultaneously, CD4+ T cells, 
activated by exposure to a peptide derived from the same antigen in the context 
of MHC Class II, upregulate CXCR5 and migrate toward the B cell follicles41,42.  
 The original Th1/Th2 paradigm subdivides T cell immunity in into two 
subsets specialized to regulate cell-mediate immunity (Th1) versus those that 
mediate B cell antibody production (Th2)43. Th1 cells mediate immune responses 
to intracellular pathogens through their secretion of IL-12 and IFN-γ44,45. On the 
other hand, Th2 cells mediate responses to extracellular parasites through the 
secretion of IL-4, IL-5, and IL-1343. Moreover, T cell help for antibody production 
had been considered a property of Th2 cells46,47. Interestingly, mice deficient in 
signal transduction and activator of transcription 6 (STAT6), a Th2 transcription 
factor important for IL-4 signaling, were still capable of mounting T-cell 
dependent antibody responses, although IgE was not produced48. These results 
demonstrate that antibody responses can occur despite impaired Th2 responses. 
 More recently, several non-Th1, non-Th2 T cell subsets have been 
identified. These subsets include T regulatory cells (Tregs), IL-17 secreting T cells 
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(Th17), IL-9 secreting T cells (Th9), and follicular helper T cells (TFH)49-54 TFH 
were first described as a unique CXCR5+ T cell population. CXCR5 expression 
allows TFH cells to home to B cell follicular areas53,54. Moreover, TFH cells are 
capable of providing B cell help for antibody production53,54.  
 The discovery of TFH cells raises several questions: (1) How do TFH cells fit 
within the Th1/Th2 paradigm? (2) How do we explain all the previous data 
implicating Th2 cells as helper cells for antibody production? A key question is 
whether TFH represent a unique lineage or whether they represent a CXCR5+ 
subset of T helper cells suggesting plasticity in T cell subsets and the cytokine 
mode. Moreover, even if they are a distinct lineage, there is a body of evidence 
of T cell plasticity. Therefore, one could hypothesize that Th2 cells could become 
TFH cells, and vice versa55-62.  
 Studies have demonstrated that TFH development requires antigen-
specific priming by DCs involving ICOS-ICOSL interaction63-65. Moreover, full 
commitment to a TFH phenotype requires B cell and T cell interaction63. The 
expression of the adaptor molecule SAP (SLAM-associated protein) can regulate 
B cell–TFH cell contact duration and is thus essential for TFH and GC 
formation66,67. It has been proposed that IL-2 signaling, through STAT5, leads to 
effector T cell differentiation, while low IL-2 signaling allows for Bcl6 expression68-
70. Bcl6 commits T cells to a TFH phenotype while repressing Prdm1 gene 
expression and preventing T cell effector differentiations 71. In this context, TFH 
cells are referred to as helpers, while other CD4+ T cell subsets are considered 
effectors69,71,72. 
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 It has also been proposed that TFH cells are not a distinct helper T cell 
subset and that TFH development occurs subsequent to Th1, Th2, Th17, and Treg 
commitment60. In agreement with this model, it has been reported that TFH cells 
differentiate from Th2 cells in response to helminth-derived antigens73. The main 
issue with this model is that it would predict that TFH differentiation would not 
antagonize other CD4+ T cell lineages. However, Bcl6, the main TFH transcription 
factor, is capable of inhibiting other T cell differentiation pathways by blocking 
Blimp-1 expression71,74-76.  
 The models proposed above, however, might not be mutually exclusive. 
CD4+ T cells might differentiate into TFH cells directly, via DC priming and 
interaction with cognate B cells. At the same time, other Th subsets (ex. Th2) 
might be capable of differentiating into TFH cells. Although Bcl6 can inhibit the 
differentiation of other Th subsets, it is not clear whether Bcl6 can inhibit the Th 
program of already differentiated T cells. Moreover, if both these models were 
correct, they would explain how Th2 cells were previously considered the key 
providers of B cell help, as Th2 cells and TFH cells could represent that same 
cellular subset.  
 Regardless of how they differentiate, it is well accepted that within the B-T 
border B cells get help from cognate TFH cells60. The interaction between cognate 
and T and B cells in the periphery of the B-cell follicle leads to the initiation of 
proliferation. While some cells enter the follicle and form GCs, others continue to 
proliferate and migrate toward the outer T-cell areas of lymph nodes or bridge 
channels of the spleen white pulp and initiate extra-follicular responses41,77. 
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Extra-follicular PC responses to T-dependent antigens seem to also require short 
B cell and TFH interaction33,66. Recent evidence has also showed that early 
memory B cells can develop in a GC-independent manner78,79.  
 
Class switch recombination and somatic hypermutation 
 As previously mentioned, one of the events that occurs within GCs is class 
switch recombination. Class switch recombination (CSR), also termed antibody 
class switching, is an irreversible genetic recombination event that changes 
antibody from one class to another, for example, from IgM to IgG. While CSR 
does not change antigen specificity, it changes the function of the antibody, as 
the constant region determines most antibody functions. Briefly, activation-
induced cytidine deaminase (AID; also known as AICDA) deaminates cytosine 
residues within the antibody switch (S) regions following germline transcription80. 
Deamination then triggers the recruitment of the base excision repair (BER) 
machinery, leading to uracil removal and single-strand breaks  (SSBs)80. UNG, 
an enzyme involved in the BER pathway, is particularly important for CSR. 
Indeed, UNG deficient mice and patients with UNG mutations have a 95% 
reduction in CSR81,82. If the SSBs are near each other on opposite DNA strands, 
they destabilize the DNA, forming double stranded breaks (DSBs). However, if 
they do not destabilize the DNA, they are repaired or converted to DSBs by 
mismatch repair activity, another DNA repair pathway. DNA breaks then lead to 
recombinations/translocations via non-homologous end joining (NHEJ)80.  
 Cytokines determine the isotype to which a B cell will switch through the 
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induction of germline transcripts. While germline transcripts are sterile RNAs, 
meaning that they do not encode proteins, they are thought to direct AID to a 
specific S region. Germline promoters have cytokine-responsive elements, 
therefore, they can be induced by cytokines80. It is in this way that different 
cytokines drive commitment to different antibody classes. For example, IL-4 
promotes IgG1 (IgG4 in human) and IgE class switching; interferon-γ (IFNγ) 
induces IgG2a (in mice only); and transforming growth factor-β (TGFβ) leads to 
IgA in both mice and humans40-42,80. While cytokines and innate stimuli alone can 
drive B cell class switching, especially in vitro, typical responses require cognate 
T cell help. Studies have demonstrated that antibody class switching can occur in 
both GC and extra-follicular pathways80. Class switch recombination, however, is 
likely to occur more efficiently within GCs given the cytokine milieu. 
 AID is not only required for CSR, but it also drives somatic 
hypermutation83. Much like during CSR, AID is required for cytosine deamination 
generating uracils and recruiting the somatic hypermutation machinery. These 
changes target the variable regions of antibody genes. Uracil DNA glycosylate 
(UNG) can then remove the uracil residues. DNA is subsequently processed by 
error-prone DNA replication leading to the introduction of point mutations in the 
actively transcribed immunoglobulin locus84. These mutations are likely to 
change the binding of immunoglobulin to antigen, thus producing clones that with 
increased or decreased affinity for antigen. Those clones that bind antigen with 
high affinity will be selected. Therefore, it is said that somatic hypermutation 
drives affinity maturation. While somatic hypermutation (SHM) occurs mostly 
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within GCs, SHM has also been reported to occur outside of GCs as evidence by 
the fact that some mice deficient in GCs exhibit affinity maturation with certain 
types of immunizations85-88. DNA damage can trigger apoptosis. In order to allow 
for rapid proliferation and SHM, GC B cells express anti-apoptotic proteins, such 
as Bcl6 and myeloid cell leukemia sequence 1 (mcl-1)89,90. 
 As previously mentioned, AID is essential for SHM and CSR to occur. 
Given that AID activity leads to mutations and changes in chromosomal 
sequence, it is important for these mutations to be targeted to a specific area 
instead of occurring throughout the genome. Studies have demonstrated that AID 
preferentially deaminates the cytosine in WRC (W=A or T, R=purine), the AID 
hotspot target. Variable and switch regions contain a large number of AID 
hotspots80,91. However, it has been reported that AID is also able to deaminate 
cytosines not present within hotspots. Moreover, not all hotspots are targeted80. 
These findings demonstrate that there is another mechanism underlying AID 
specificity that has yet to be described. Moreover, what prevents AID from being 
expressed in cells other than B cells is poorly understood. 
 
Affinity maturation 
 Studies have demonstrated that GC B cells continuously sample FDC 
networks that are laden with immune complexes that form when several 
antibodies bind soluble antigens. This B cell – FDC interaction is important for B 
cell survival92-94. Following FDC scanning, a few GC B cells make stable contacts 
with GC TFH cells94. While high affinity clones are selected within GCs, B cells 
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expressing BCRs with low affinity for the antigen undergo apoptosis95. How B 
cells with high affinity for antigen are selected is not fully understood. There are 
currently two competing models describing selection of B cell expressing high 
affinity BCRs: (1) BCR signal-based selection (classical model) and (2) BCR 
signal and T cell help-based selection37.  
 In the classical model, B cells compete for antigen binding in the form of 
immune complexes displayed on the surface of FDCs. GC B cell fate is 
dependent on the degree of interactions with antigen. If BCR signaling is too 
weak or too brief, the cell will undergo apoptosis – ‘death by neglect’96. Apoptotic 
bodies are cleared by tingible body macrophages. FDCs are thought to control 
the engulfment of apoptotic bodies97. If BCR signal is of sufficient strength, the 
GC B cell will be selected. These selected cells could then present antigen to TFH 
cells and this interaction could enhance GC B cell survival and/or stimulate the 
differentiation into ASC or memory B cell37,96. In this model, GC B cell selection is 
dependent on BCR signaling strength and the interaction between GC B cells 
and FDCs. The small number of surviving cells would then interact with TFH cells 
and further differentiate.  
 Another model has been recently proposed. This model suggests that B 
cell- TFH interactions are important for selection of GC B cells expressing BCRs 
with high affinity for the antigen. As in the classical model, GC B cells compete 
for antigen binding on the surface FDCs. Those cells that receive an adequate 
BCR signal survive, while those with inadequate BCR signal undergo apoptosis. 
Contrary to the classical model, however, the T-cell based selection model 
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argues that surviving GC B cells compete for T-cell help. Only those cells with 
high affinity BCRs are capable of receiving enough T cell help to survive and 
differentiate37. It has been proposed that the interaction between GC B cells and 
TFH cells is the limiting factor in the selection of clones with high-affinity BCRs37. 
It is, therefore, likely that both GC B cell – FDC and GC B cell – TFH interactions 
are important for the selection of B cells expressing high affinity BCRs. Moreover, 
recent studies have suggested that TFH cells and FDCs also interact, however, 
whether these interaction occurs and its role in humoral responses has yet to be 
determined98.  
 
Other factors involved in GC formation and maintenance 
 There are many molecules that have been associated with GC formation. 
Bcl6 expression, in both B cells and TFH cells, is required for GC development99-
101. Bcl6 is a transcriptional repressor. Within GC B cells, Bcl6 is required to 
prevent apoptosis in response to DNA damage that occurs during CSR and 
SHM102. It has also been suggested that Bcl6 is required to halt plasma cell 
differentiation until a cell has acquired sufficient affinity31. Studies have 
demonstrated that IL-6 signaling can induce Bcl6 expression103,104. In the context 
of a GC, IL-6 is produced by activated FDCs and promotes SHM and affinity 
maturation105.  
 IL-21, the main cytokine produced by TFH cells, plays a key role in GC 
formation and plasma cell differentiation78,106. Initially, mice deficient in either IL-
21 or IL-21R were reported to have profound defects in antigen-specific IgG 
 18 
production despite normal GC formation107. Detailed analysis demonstrated that 
IL-21 deficient mice show decreased GC persistence78,106. Interestingly, normal 
memory B cell were produced in IL-21 deficient mice106. STAT3, which acts 
downstream of IL-21, as well as IL-6, IL-2, and IL-10, is essential for the 
generation of IgG1 secreting cells108. IL-21, through STAT3 is able to trigger 
Blimp-1 expression109,110, and could be involved in plasma cell (PC) 
differentiation (see section 1.4). 
  
Germinal Center Structure 
 Given the key role cell-cell interactions play in GC formation, affinity 
maturation, and plasma cell differentiation, the organization of the GC is essential 
for humoral responses. GCs have two zones, called the dark and light zone, 
based on their initial histological appearance111. FDC, TFH and few GC B cells 
occupy the light zone, while the dark zone is composed of closely packed GC B 
cells. The chemokine receptor CXCR4 is required for GC B cell positioning within 
the dark zone. Its ligand, CXCL12, is more abundant in this zone than in the light 
zone37. CXCL13 is highly expressed within the light zone, where it accumulates 
in the processes of FDCs17. CXCL13-mediated CXCR5 signaling seems to be 
important for GC B cell positioning within the light zone. Previously, GC B cells 
have been thought to move preferentially from the dark to the light zone. 
However, recent studies have demonstrated GC B cells can also migrate from 
dark zone to light zone. Moreover, B cells are also capable of intra-zonal 
movement, for example, dark zone B cells can move within the dark zone93.  
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 It has been recently described that sphingosine-1-phosphate receptor 2 
(S1P2) is required for GC B cells to stay within GC niche112. It has been proposed 
that a gradient of sphingosine-1-phosphate (S1P), with highest concentrations 
outside of GC and at the GC boundary, prevent GC B cell migration by mediating 
S1P2-mediated inhibition of migration113.  
 
Extra-follicular vs. GC pathway 
 Antigen-activated B cells that do not give rise to antibody-secreting cells in 
an extra-follicular fashion can initiate GCs36,37. What commits a B cell to the 
extra-follicular or GC-pathway is unclear, but it has been proposed that BCR 
affinity for antigen, the amount of antigen-BCR interaction, and co-stimulatory 
signals received from T cells might all play a role114-118. It has been proposed that 
B cells with highest affinity differentiate into PCs in an extra-follicular manner, 
while lower affinity B cells enter GCs where they mature and undergo affinity 
maturation117. Whether FDCs play a role in the selection of the B cells that will 
enter GCs is unknown.  
 Extra-follicular PC differentiation occurs early in an immune response. As 
extra-follicular responses begin to decrease, long-lived PCs and memory B cells 
begin to appear96. PCs of extra-follicular origin tend to be short-lived and are 
non-migratory, while long-lived PCs reside in the BM where they secrete 
antibody for several weeks or longer119,120.  Interestingly, most long-lived PCs 
show large numbers of somatic mutations, suggesting that they are GC-
derived39,96,121..  
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Post-GC cells 
 The outcome of GCs are antibody secreting PCs and non-
immunoglobulin-secreting memory B cells. While PCs secrete large quantities of 
antigen-specific antibodies, memory B cells undergo rapid proliferation and 
differentiation to high affinity PCs upon secondary antigen encounter. It has been 
suggested that the increased affinity of the BCR on memory cells leads to high 
sensitivity to low-dose soluble antigens that do not induce primary responses. 
Moreover, recent studies have suggested that memory B cells can re-initiate GC 
reactions following antigen challenge122, although is unclear whether this 
secondary GC is a re-expansion of a primary GC or a newly developed GC. This 
is consistent with the concept of original antigenic sin. It describes that secondary 
antigen exposures preferentially induce a memory response, while primary 
responses are downregulated/inhibited123. The molecular changes involved in 
memory B cell differentiation are not well characterized. Moreover, what 
determines whether a GC B cell will become a PC or a memory B cell is not well 
understood. 
 
1.4 Plasma cell differentiation 
 One of the hallmarks of PC differentiation is a switch from transcription 
factors that control mature B-cell gene expression programs, such as Pax5 and 
Bcl6, to those that dictate PC program, such as B lymphocyte induced maturation 
protein 1 (Blimp-1), XBP-1, and interferon regulatory factor 4 (irf4)31. While it is 
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well established that these sets of transcription factors repress each other, it 
remains unclear how B cells switch from a mature B cell program to a PC one. 
 Pax5 is a transcription factor that is expressed throughout the B cell 
lineage and in all mature B cell subsets55. It is essential for both the 
establishment and maintenance of B-cell identity. It can activate genes involved 
in immunoglobulin gene rearrangement, BCR signaling, affinity maturation, and 
SHM. Moreover, Pax5 represses the transcription of genes that are important for 
PC development and function, such as Xbp-1124. 
 Blimp-1 triggers terminal B cell differentiation by repressing genes 
required for GC reactions and inducing genes involved in Ig secretion76. It is, 
therefore, important for Blimp-1 not to be expressed prematurely. Bcl6 has been 
shown to repress prdm1, the gene encoding for Blimp-1, in both a direct and 
indirect fashion68,70. Therefore, timely downregulation of Bcl6 is critical for PC 
differentiation. Studies have demonstrated that BCR cross-linking induces Bcl6 
phosphorylation and subsequent degradation125. This de-repression of Blimp-1, 
as well as STAT3 activation via cytokines secreted by TFH cells, such as IL-21, 
could lead to Blimp-1 expression109. 
 Blimp-1 is a transcriptional repressor often referred to as the “master 
regulator” of PC differentiation. Studies have demonstrated that Blimp-1 is 
sufficient to induce plasmacytic differentiation in vitro72. When Blimp-1-deficient 
mice were immunized with either a T- dependent or T–independent antigen, the 
number of Ig secreting cells and serum Ig levels were dramatically decreased 
compared to control mice126,127. Moreover, deletion of Blimp-1 in mature PCs 
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resulted in plasma cell apoptosis127. Blimp-1 represses mature and GC B-cell 
genes, such as Pax5, Bcl6, and AID. Moreover, Blimp-1 leads to the expression 
of genes important for plasma cell development and function, such as Ig genes 
and XBP-1. Furthermore, Blimp-1 leads to the upregulation of CXCR4, a 
chemokine receptor important for homing and maintenance of PCs in vivo75. 
Interestingly, studies have demonstrated that Blimp-1 is not necessary to initiate 
the process of plasma cell differentiation, as ‘pre-plasmablasts’ could be 
generated in the absence of Blimp-176,128,129. Plasmablast are PC precursors that 
express mature B cell makers, such as B220 and CD19, although to a lower 
degree than naïve B cells130. 
 Irf4 is highly expressed in all PCs and it is essential for PC 
differentiation131,132. While Irf4 is not required in B cells for GC formation, it 
promotes isotype switching within GCs132. Irf4 is upregulated following B cell 
activation. At low levels, it promotes AID expression and CSR and at higher 
levels, it promotes Blimp-1 expression. Consequently, Irf4-deficient B cells fail to 
induce Blimp-1131. It is likely that Irf4 plays a role in the initiation phase of PC 
differentiation.  
 Blimp-1 and IRF4 lead to cell cycle arrest and promote PC development 
133. Moreover, they permit XPB-1 (X box binding protein-1) expression132,134. 
XBP-1 is thought to be expressed following Blimp-1, since XBP-1 deficient B 
cells express normal Blimp-1 levels following activation124,135. XBP-1 plays an 
important role in mammalian unfolded protein response (UPR), a series of events 
that allow for endoplasmic reticulum (ER) expansion and allow cells to handle 
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extensive protein production136 as in the case of PCs. While the number of PCs 
was normal in XBP-1 deficient mice, serum antibody levels were severely 
impaired following antigen challenge. Phenotypically, however, these plasma 
cells showed reduced ER, consistent with the decrease in protein 
production124,135. These results demonstrate that XBP-1 is not needed for plasma 
cell development but is essential for antibody secretion.  
 The survival and differentiation of plasmablasts and PCs are dependent 
on B-cell activation factor (BAFF) and a proliferation inducing ligand (APRIL), 
members of the tumor necrosis factor (TNF) family137. Indeed, mice deficient in 
BAFF, APRIL, or B cell maturation antigen (BCMA), one of the receptors for 
these cytokines, demonstrated the key roles of these factors in the development 
and maintenance of PCs, as PC numbers were severely impaired in these mice 
compared to controls138-140. Studies have demonstrated that within the murine 
bone marrow, eosinophils are the main source of these cytokines. Moreover, 
they have demonstrated that eosinophils are essential for PC survival141.  
 Many of the mechanisms underlying B cell development, GC formation 
and PC differentiation are still unknown. Here, we aimed to identify the role of 
two distinct proteins, ADAM10 and Fyn, in B cell biology. ADAM10 is a 
membrane of the family of disintegrin and metalloproteinases, and as such, it 
mediates the cleavage of trasnmembrane proteins. Previous studies have 
demonstrated a role for ADAM10 in B cell development24. We, therefore, 
hypothesized that ADAM10 was involved in humoral responses. Here we 
demonstrate that B cell expressed ADAM10 regulates lymphoid architecture, GC 
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formation and PC development (See chapter 3). Fyn is a member of the Src-
family kinase. Previous studies have implicated Fyn in antibody responses, but 
the role of Fyn in GC formation had yet to be determined142,143. Here we 
demonstrate that Fyn is required for optimal GC formation. Fyn-deficient mice 
show impaired antibody responses. Moreover, Fyn-deficient B cells produce less 
antibodies than their wild type counterparts when activated in vitro, suggesting a 
B-cell intrinsic defect (See chapter 4).   
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CHAPTER 2: MATERIAL AND METHODS 
 
2.1 Mice 
 ADAM10B-/- mice were previously described24. To generate ADAM10B-/-
N2ICD-TgB+, ADAM10B-/- mice were mated with N2ICD-Tgflox/flox mice144. CD19-
cre- mice were wild type littermates of ADAM10B-/-  and ADAM10B-/-N2ICD-TgB+ 
mice. CD23Tg mice have been previously described145. Balb/CJ mice were used 
as littermate controls of CD23Tg mice. Fyn-KO mice were previously described, 
and B6.129 mice were used as WT controls146. In order to generate 
ADAM10Δ/ΔIgG1-cre+/-YFP+ mice, ADAM10Δ/ΔYFP+ mice were mated with IgG1-
cre+/-128 mice that were purchased from Jackson mice. ADAM10+/+IgG1-cre+/-
YFP+ mice were used as controls. To generate ADAM10Δ/Δ mb1-cre+/-YFP+ mice, 
ADAM10Δ/ΔYFP+ mice were mated with mb1-cre+ mice, kindly provided by 
Michael Reth through the laboratory of David Allman147. CX3CR1-deficient mice 
were purchased from Jackson Laboratory148. All mouse protocols were approved 
by the Virginia Commonwealth University Institutional Animal Care and Use 
Committee. 
 
2.2 PCR and Quantitative PCR 
PCR 
 For genotyping, DNA was isolated using Direct PCR Solution as directed 
by the manufacturer (Viagen). MangoMix (Bioline) was used for amplification of 
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mb1, IgG1, and CD19 cre-lines, ADAM10-floxxed alleles, and YFP and N2ICD 
transgenes. Cycling conditions were as follows, 95°C for 3 min, 35 cycles of 94°C 
for 1 min, 55°C for 1 min, 72°C for 2 min, and final extension at 72°C for 10 min. 
Sequences of all primers described above are listed in Table 1. 
 
Quantitative PCR 
 Total RNA was extracted and purified from draining and non-draining 
mouse lymph nodes (LNs) using TRIzol reagent (Invitrogen). Samples were 
treated with DNase (Takara Bio), mixed with phenol/chloroform/isoamyl alcohol 
solution (25:24:1; USB), and precipitated with ethyl alcohol. The purity of RNA 
was quantified by a spectrophotometer (ND-100; NanoDrop). One microgram of 
RNA was reverse transcribed using the High Capacity cDNA RT kit (Applied 
Biosystems). Real-time quantitative PCR was performed with a real-time PCR 
machine (iQ5; Bio-Rad Laboratories). Primers and probes for running a TaqMan 
quantitative PCR assay were purchased from Applied Biosystems. TaqMan gene 
expression assays used included: CCL19: Mm00839967_g1, IL-21: 
Mm00517640_m1, Aidca: Mm01184115_m1; Xbp1: Mm00457357_m1, Prdm1: 
Mm00476128_m1, Bcl6: Mm00477633_m1; and Irf4: Mm00516431_m1. Primers 
for CCL21 were synthesized by IDT as previously described149. PCR products, 
labeled with 6-FAM–conjugated probes, were amplified with 18S as an internal 
control. Reaction parameters were as follows: hold at 48 ̊C for 30 min and hold at 
95 ̊C for 10 min, followed by 40 cycles of 95 ̊C for 15 s and 60 ̊C for 60s. Results 
were analyzed with iQ5 real-time PCR software (version 2.0). Sequences of all 
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primers and probes, except those included in purchased Taqman gene 
expression assays described above, are listed in Table 1. 
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Table 1. Primer and probe sequences.  
S- sense, AS- anti-sense 
PCR 5’3’ 
ADAM10: Intron8 CAGTGTAAATGTGAACTCACCC 
ADAM10: Intron9 CGTATCTCAAAACTACCCTCCC 
N2ICD: N2AD1 CCTTATGATGTTCCCGATTATGC 
N2ICD: N2AD2 AGTACACCCATCTGGGCCTCG 
YFP:oIMR4982 AAGACCGCGAAGAGTTTGTC 
YFP: oIMR8545 AAAGTCGCTCTGAGTTGTTAT 
YFP: oIMR8546 GGAGCGGGAGAAATGGATATG 
CD19-cre: oIMR1084 GCGGTCTGGCAGTAAAAACTATC 
CD19-cre: oIMR1085 GTGAAACAGCATTGCTGTCACTT 
IgG1-cre: 9264 TGTTGGGACAAACGAGCAATC 
IgG1-cre: 9265 GTCATGGCAATGCCAAGGTCGCTAG 
IgG1-cre: 9266 GGTGGCTGGACCAATGTAAATA 
Mb1-cre: hCre dir CCCTGTGGATGCCACCTC 
Mb1-cre: hCre rev GTCCTGGCATCTGTCAGAG 
Quantitative PCR  
18S S AAAATTAGAGTGTTCAAAGCAGGC 
18S probe CGAGCCGCCTGGATACCGCAGC 
18S AS CCTCAGTTCCGAAAACCAACAA 
CCL21 S AGACTCAGGAGCCCAAAGCA 
CCL21 AS GTTGAAGCAGGGCAAGGGT 
CCL21 probe CCACCTCATGCTGGCCTCCGT 
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2.3 Immunization.  
 For all immunization protocols, mice were of 6-12 weeks of age, unless 
otherwise stated. When experiments were terminated, mice were sacrificed via 
isofluorane inhalation and cervical dislocation. All mouse protocols were 
approved by the Virginia Commonwealth University Institutional Animal Care and 
Use Committee.  
 
T-dependent immunizations.  
 For T-dependent immunization protocol, mice were immunized with a 
single 10 µg 4-Hydroxy-3-nitrophenylacetyl injection coupled to keyhole limpet 
hemocyanin at a ratio of 27:1 (NP27KLH – from this point called NP-
KLH)(Biosearch Technologies). For memory protocols, mice were then given a 
second immunization of 10 µg of NP-KLH 42-49 days after primary immunization. 
For i.p. injections, mice were given 200µL of immunization mixture, made as 
follows: 10µg of NP-KLH in 100µL of PBS and 100µL of alum (4mg). For footpad 
injections, mice were given 25µL of immunization mixture, made as follows: 10µg 
of NP-KLH in 10µL of PBS and 15µL of alum (0.6mg).  Mice were bled weekly via 
tail vein nick and cardiac punctured when the experiment was terminated.   
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T-independent immunizations.  
 Mice were immunized with 100 µg of NP0.6LPS (Biosearch Technologies) 
i.p. in 100µL of PBS. Mice were bled weekly via tail vein nick and cardiac 
punctured when the experiment was terminated.   
 
Immune Complexes.  
 Mice were passively immunized subcutaneously (s.c.) in the nape of the 
neck with 6mg of rabbit polyclonal anti-OVA antibodies in 400µL of PBS 
(Meridian Life Sciences). Twelve hours later, mice were immunized with 100µg 
NP24OVA s.c. in alum. Immunization mixture consisted of 100µg of NP24OVA in 
PBS and 100µL of alum (4mg). Six days following immunization mice were 
sacrificed and cardiac punctured. 
 
 The different NP-conjugates used are summarized in Table 2.  
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Table 2. NP-conjugated antigens 
Antigen Use 
NP27KLH T-dependent immunization  
NP4BSA High affinity NP-specific ELISA/ELISPOT 
NP14BSA Total NP-specific ELISA/ELISPOT 
NP0.6LPS T-independent Immunization 
NP24OVA Immune complexes studies 
  
  
 32 
2.4 Cell isolation 
Tissue Preparation 
 Single cell suspensions of peripheral lymph node (LN) cells and 
splenocytes were generated by disrupting tissue between glass slides. BM cells 
were isolated by flushing excised tibias and femurs with complete RPMI. Red 
blood cells were then lysed by using ACK lysis buffer. Cells were then plated or 
stained depending on the experimental design.   
 
B cell and Plasma Cell isolation 
 Cellular isolations were carried out using magnetic bead (Miltenyi Biotec). 
Briefly, single cell suspension was generated as previously described (see tissue 
preparation). Cells were resuspended in MACS buffer (PBS pH 7.2, 0.5% BSA 
and 2mM EDTA) and incubated with the corresponding magnetic beads for 15 
minutes at 4°C. Cells were then washed and passed through a magnetic column. 
When cells were isolated via negative selection, LD columns were used and flow-
through was harvested. On the other hand, when cells were isolated via positive 
selection, LS columns were used. In this case, after cells were passed through 
the column, columns were washed and flushed with MACS buffer and the eluted 
cells were utilized for experiments. When a small number of cells were isolated 
via positive selection, MS columns were used. For B cell isolation, cells were 
isolated via positive selection (B220+ cells) for all cells or via negative selection 
(CD43-) for isolation of naïve or untouched B cells. PCs were isolated via 
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negative selection (B220-DX5- cells) and subsequent positive selection (CD138+ 
cells). 
 
Stromal Cell Isolation 
 In order to isolate LN stromal cells, lymph nodes were processed by 
enzymatic digestions. Protocol was carried out as previously described, with 
minor modifications150 LN were isolated, cut in small pieces with micro-scissors 
and place in RPMI-1640 on ice. After all LN were dissected, media was removed 
and replaced with 2mL of freshly made enzyme mix. Enzyme mix consists of 
0.8mg/mL Dispase (Roche), 0.8mg/mL collagenase IV (Invitrogen) and 
0.1mg/mL DNase I (Invitrogen) in RPMI-1640. Cells were incubated at 37°C in a 
water bath for 20 minutes; gently inverting at 5 minute intervals to ensure the 
content were well mixed. The LN were then gently aspirated and expirated to 
disrupt the capsule. Large fragments were allowed to settle and the enzyme mix 
was then removed and added to 10mL of ice-cold FACS buffer (PBS with 2% 
FBS). 2mL of fresh enzyme mix was added to the digestions tube and gently 
mixed. Tubes were then incubated for 10 min at 37°C. Cells were then mixed 
vigorously for 30 seconds. As previously, large fragments were allowed to settle 
and enzyme mixed was removed and transferred to the tube containing 10mL of 
ice-cold FACS buffer. 2mL of fresh enzyme mix was then added to digestions 
tube. Tube was incubated at 37°C and mixed vigorously every 5 minutes until all 
lymph node fragments were completely digested. All supernatants were then 
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combined and spun down 1200 RPM for 5 minutes. Cells were then analyzed via 
flow cytometry (see section 2.6). 
 
2.5 Enzyme Linked Immunosorbant Assay (ELISA) and Enzyme Linked 
Immunosorbant Spot (ELISPOT) 
Total antibody levels.  
 For total Ig ELISAs, ELISA plates were coated with 5 µg/mL of goat-anti Ig 
(Southern Biotech) in BBS (0.15 M sodium chloride, 0.01 M borate buffer, 
pH=8.5). Plates were then incubated at 37°C for an hour or at 4°C overnight. 
Plates were then washed three times with ELISA wash (PBS with 0.02% Tween-
20). Blocking solution (PBS with 0.02% Tween-20 and 2% FBS) was added to 
plates. Plates were then incubated at 37°C for an hour or at 4°C overnight. Plates 
were then washed three times with ELISA wash and samples were added, 
diluted in block. For standard curve, normal mouse Ig (Southern Biotech) was 
used. Plates were then incubated at 37°C for an hour or at 4°C overnight. Plates 
were then washed three times with ELISA wash and goat-anti-Ig-alkaline 
phosphatase (AP) was added to plates. Goat-anti-Ig-AP was diluted in block 
(1:400 dilution) (Southern Biotech). After 1 hour incubation at 37°C, plates were 
washed and developed with phosphate tablets (sigma) dissolved in substrate 
buffer (0.1g MgCl2.6H20, 0.2g NaN3, 50mL diethanolamine, pH to 9.8 per 
500mL). Absorbance at 405nm was measured.  
 35 
NP-specific ELISA.  
For NP-specific ELISAs, ELISA was carried out as previously described with 
minor modification. Plates were coated with NP14BSA (Biosearch 
Technologies)(15 µg/mL in PBS) for samples and with 5 µg/mL of goat-anti Ig 
(Southern Biotech) in BBS for standard. The remaining steps were carried out as 
previously described (see total antibody levels). For measurement of high affinity 
antibodies, protocol was carried out as described except that plates were coated 
with NP4BSA (Biosearch Technologies; 15 µg/mL). While only high affinity 
antibodies can efficiently bind NP4BSA, both low and high affinity antibodies bind 
NP14BSA. The described NP-specific ELISA protocol allows for the relative 
quantification of high vs. low affinity antibodies151. 
 
TNF-α ELISA 
 TNF-α levels were measured by ELISA using a TNF-α ELISA assay kit 
(Peprotech) and following manufacturer’s instructions.  
 
ELISPOT.  
 For ELISPOT, 96-well MultiScreen filtration plates (Millipore) were coated 
with 15 µg/mL of NP4BSA or NP14BSA in PBS. Plates were then incubated at 4°C 
overnight. Plates were then washed with PBS three times and complete RPMI 
was added to the plates. Plates were then incubated with media for at least 3 
hours at 37°C. Meanwhile, splenic, LN, and BM cells were made into a single cell 
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suspension, as previously described (see section 2.4). Cells were seeded into 
the plate in duplicate, with at least three serial dilutions, and cultured for 18 hours 
at 37 °C in 100µL of complete RPMI. Plates were developed as previously 
described152. Briefly, following incubation, plates were washed three times with 
0.02% Tween-20 in PBS and incubated for 2 hours at 37°C with biotinylated anti-
Ig (1:1000 dilution in PBS) (Southern Biotech). During the incubation, APC 
solution was prepared following manufacturer instructions (VECTASTAIN Elite 
ABC system, Vector Laboratories). APC solution was incubated for at least 30 
minutes prior to addition to ELISPOT plates. Following incubation, plates were 
then washed as before. Plates were then incubated with APC solution for 1 hour 
at room temperature. During the incubation, AEC Solution was prepared. AEC 
solution consists of one 3-Amino-9-ethylcarbazol (AEC) tablet dissolved in 2.5mL 
of dimethylformamide (DMF). After tablet dissolved, 47.5mL of acetate buffer 
(0.1N acetic acid and 0.1M sodium acetate) and 25µL of H2O2 were added. 
Following incubation with APC solution, plates were washed and AEC solution 
was added. Following a 4-minute incubation at room temperature, the reaction 
was stopped by rinsing the plates with water. Plates were then allowed to dry 
overnight, and spots were counted under dissecting a microscope. It should be 
noted that the number of cells plated and time of incubation were optimized. 
These parameters are affected by immunization protocol and immunoglobulin 
isotype of interest. Generally, total antigen-specific IgG and IgM are readily 
detected when cells are incubated for 18 hours at concentration of 0.5x106 
cells/well, 21 days post-immunization. 
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2.6 Flow cytometry, immunofluorescence and confocal microscopy.  
Flow cytometry 
 Cell isolation was conducted as described previously (see section 2.4 Cell 
Isolation). Cells were labeled following RBC lysis and filtration through 40µm cell 
strainers. For surface staining, cells were washed in FACS buffer (2% FBS in 
PBS). 1-3x106 cells were re-suspended in 50-100µL. Cells were then incubated 
on ice with 1-5µg of Fc block (2.4G2) for 10 minutes to prevent non-specific 
staining. Subsequently, cells were incubated for 30 min on ice with different 
combinations of 0.25-0.5µg of anti–mouse antibodies. Cells were then washed 
with FACS buffer and analyzed. For intracellular staining, staining was carried 
out using PhosphoFlow kit (BD). Briefly, cells were stained extracellularly as 
described. Cells were then washed with FACS buffer and fixed by the addition of 
2mL of pre-warmed Lyse/Fix buffer (1X) and incubation at 37° C for 10 minutes. 
Cells were then washed with FACS buffer and permealized with 1mL of 
Perm/Wash buffer for 15-30 minutes at room temperature. Following 
permealization, cells were washed and resuspended in 50-100µL of Perm/Wash 
buffer. Cells were incubated with 1-5µg of Fc block (2.4G2) in Perm/Wash buffer 
for 5 minutes at room temperature. Subsequently, cells were incubated for 45 
minutes with anti-mouse antibodies. Cells were then washed with Perm/Wash 
buffer, resuspended in FACS buffer, and analyzed. Flow cytometry analysis was 
performed using a Canto or AriaII (BD Biosciences) using Diva at the Flow 
Cytometry Core at Virginia Commonwealth University. Expert technical 
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assistance by Julie Farnsworth is acknowledged. Flow cytometry data analysis 
was conducted with FlowJo v8.8.7 (Tree Star).  
 
Immunofluorescence and confocal microscopy.  
 Spleen and LN were frozen on dry ice in OCT compound (Tissue-Tek; 
Sakura). Serial 10µm sections were cut from frozen blocks using a cryostat 
(Frigocut 2800E; Jung), fixed in absolute acetone, and air-dried. Sections were 
blocked with 10% BSA in PBS to prevent background staining and then washed 
and incubated for 60 min with different combinations of 2-5 µg/ml anti–mouse 
antibodies. Sections were washed, mounted with anti-fade mounting medium 
(Vectashield; Vector Laboratories), cover slipped, and examined with a confocal 
laser scanning microscope (TCS-SP2 AOBS; Leica) fitted with an oil Plan-
Apochromat 40× objective. Two lasers were used: argon (488 nm) for FITC, and 
HeNe (543 nm) for PE and APC. Parameters were adjusted to scan at a 512 × 
512 pixel density and an 8-bit pixel depth. Emissions were recorded in three 
separate channels. Digital images were captured, overlaid, and processed with 
the Confocal and LCS Lite programs (Leica). 
 
Antibodies.  
All antibodies are anti-mouse, unless otherwise noted. 
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Table 3. Flow cytometry and Immunohistochemistry antibodies 
Specificity Clone Label Source 
ADAM10  PE, FITC R&D 
B220/CD45R RA3-6B2 FITC, PE, APC, PE-Cy7, 
Alexa 674, Alexa 700, 
PerCP/Cy5.5 
Biolegend 
BCL6* K112-91 PE BD Bioscience 
CCL21  Unlabeled R&D 
CD16/32 2.4G2 Unlabeled Conrad Lab 
CD19 6D5 PE, APC, PerCP/Cy5.5 Biolegend 
CD21/CD35 7G6 PE Biolegend 
CD31 MEC13.3 APC Biolegend 
CD38 90 PE-Cy7 Biolegend 
CD4 RM4-5 APC Biolegend 
CD4 H129.19 PE Biolegend 
CD43 1B11 PE-Cy7 Biolegend 
CD45 30-F11 FITC Biolegend 
CXCR5 RF8B2 Biotin BD Biosciences 
Fas (CD95) Jo2 PE BD Bioscience 
GL7 (B and T 
activation marker) 
GL7 FITC, APC eBioscience, BD 
Bioscience 
gp38 (podoplanin) 8.1.1 PE Biolegend 
IgD 11-26c.2a PE, PerCP/Cy5.5 BD Biosciences 
IgG1 A85-1 APC, PE BD Bioscience 
IgM RMM-1 PE, APC, APC-Cy7, 
PerCP/Cy5.5 
Biolegend 
Thy1.2 30-H12 FITC Southern Biotech 
 
*Anti-human, cross-reactivity with mouse Bcl6.  
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2.7 In vitro activation 
In vitro activation of antibody production 
For IgG1 and IgE production, B cells or splenocytes were cultured with CD40L-
transfected Chinese hamster ovary (CHO) cells as a B cell stimulant (6x104 
cells/well) or with 1µg/mL of stimulating anti-CD40 antibody (Invitrogen) and IL-4 
(10,000U/mL) for seven days. Supernatants were then harvested and analyzed 
for IgG1 and IgE production by ELISA. Cells were also stimulated with 50µg/mL 
of LPS (sigma). Four days later, supernatants were harvested and analyzed for 
IgM and IgG3 production. 
Proliferation 
To determine proliferation, cells were isolated and stimulated as described (see 
above). After 96 hours in culture, cells were pulsed with 1 µCi/well of tridiated 
([3H])-thymidine (Perkin Elmer) for 24 hrs. Plates were then harvested onto GFC 
plates using a filtermate cell harvester. Plates were dried for at least 2 hours, 
25µL of scintillation fluid was added, and counts were determined using the 
Topcount Plate Counter (Perkin Elmer, Waltham, MA). Proliferation was reported 
as counts per minute (CPM). 
 
2.8 Migration Assay 
For B cell migration studies, spleens were harvested and made into a single cell 
suspension, as previously described in section 2.4. Cells were washed in 
migration media (RPMI containing 0.5% fatty acid free BSA and 10mM HEPES) 
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and then incubated in this medium for 30 minutes at 37°C prior to the assay. 
Migration assay was performed using 5µm transwell (Corning Costar Corp.). 
Briefly, 600µl of media containing 1µg/mL of CXCL13 (Peprotech), 300ng/mL of 
CXCL12 (Peprotech), or just media was added to the lower chamber. After 
insertion of the filter, 1x106 cells were added to the top chamber in 100µL. After 3 
hours at 37°C, cells in the lower chamber were analyzed by flow cytometry. Cells 
were stained and resuspended in 60µL of FACS buffer. Events were collected at 
a high flow rate for 60 seconds. For the calculations of specific migration, a 
known number of cells were added to the bottom chamber. Chemotaxis is 
expressed as percent of input cells.  
 
2.9 Statistical analysis.  
When dealing with two groups, p-values were calculated using unpaired two-
tailed Student’s t-tests in Graphpad Prism, unless samples did not form a 
Gaussian distribution, indicated by a failed D’Agostino and Pearson omnibus 
normality test. In the case of non-parametric populations, p-values were 
calculated using two-tailed Mann-Whitney test. When more than two were 
compared, p-values were calculated using a one-way analysis of variance with a 
Tukey post-test. Error bars represent the standard error of the mean (SEM) 
between samples. p<0.05 is considered significant. 
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CHAPTER 3: ADAM10 AND ITS ROLE IN EARLY B CELL DEVELOPMENT, 
GERMINAL CENTER FORMATION AND PLASMA CELL FUNCTION 
 
3.1 Introduction to ADAM10 
 ADAM10 is a member of a family of disintegrin and metalloproteinases. 
(ADAMs). ADAMs belong to the metzincin superfamily, along with matrix 
metalloproteinases (MMPs) and ADAM-thromospondins (ADAM-TS). While all 
functionally active metzincin proteases contain a zinc binding motif, ADAMs are 
unique in that they also contain a transmembrane domain and are active while 
membrane bound. ADAMs are therefore responsible for the processing of 
receptors and ligands expressed on the cell surface. ADAMs can mediate 
ectodomain shedding and regulated intramembrane proteolysis (RIP) of 
transmembrane proteins. Shedding of extracellular domains releases soluble 
fragments into the extracellular space. This cleavage event can lead to 
downregulation of events that depend on transmembrane receptor-ligand 
expression or can activate paracrine and/or autocrine signaling by the production 
of a soluble mediator, such as necrosis factor-α (TNF-α).  While ectodomain 
shedding is thought to occur constitutively, RIP requires receptor-ligand 
interaction153. The prototypical ADAM is composed of a prodomain, 
metalloprotease domain, a disintegrin domain that confers substrate specificity, a 
cysteine-rich region, a transmembrane domain, and a cytoplasmic tail87,154. A 
prototypical ADAM is depicted in Figure 2. 
 Ever since ADAM10 and its Drosophila homolog, Kuzbanian (kuz), were 
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discovered, their key role in developmental pathways has been noted. Kuz was 
initially identified in 1996. Studies of kuz-deficient embryos revealed that kuz was 
required for the development of peripheral and central nervous system. Cloning 
analysis demonstrated that the kuz gene encodes for a metalloprotease-
disintegrin, highly homologous to bovine metalloprotease, later named 
ADAM1080,155,156. Subsequent studies demonstrated that nervous system defects 
were due to defective Notch receptor signaling in the absence of kuz mediated 
RIP157. The importance of ADAM10 for mammalian development has also been 
demonstrated, likely due to the key role of ADAM10 in the initiation of Notch 
signaling. Murine studies revealed that ADAM10-deficient embryo die very early 
in development, embryonic day 9.5, with multiple defects of the developing 
center nervous system and cardiovascular system84,158 
 ADAM10 has emerged as a key mediator of ectodomain shedding and 
RIP of a large number of substrates, such as Notch receptors, CD23, and TNF-α, 
(more ADAM10 substrates are discussed in Table 4)87,153. While it is well 
accepted that ADAM10 mediates cleavage of membrane-bound substrates, 
recent evidence demonstrates that ADAM10 activity is not restricted to the 
plasma membrane. Indeed, several reports have demonstrated that ADAM10 
and a few of its substrates are present in exosomes, which are small secreted 
vesicles159,160. Moreover, it has been reported that ADAM10 is highly expressed 
in the endoplasmic reticulum (ER)161. Whether the ER represents a reservoir for 
ADAM10 or if ADAM10 is functional within this organelle has yet to be 
determined. Furthermore, it has been recently demonstrated that the intracellular 
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domain of ADAM10 can be processed by ADAM9, ADAM15 and γ-secretase, 
allowing for the ADAM10 intracellular domain (ICD) to translocate to the nucleus 
and modulate gene expression162. Recently, it has been demonstrated that 
ADAM10-ICD is involved in human prostate cancer progression and in human 
immunodeficiency virus Type-1 replication163,164. 
 Despite ADAM10’s key role in development, relatively little is known 
regarding its regulation. ADAM10 is expressed as a zymogen and is 
subsequently activated by cleavage of the pro-domain by a furin protease100,165,. 
Following activation, ADAM10 activity can be regulated in a variety of ways. 
Tissue inhibitors of metalloproteases (TIMP), including TIMP1 and TIMP3, have 
been demonstrated to inhibit ADAM10 activity in vitro166,167. Several studies have 
demonstrated that ADAM10 proteolytic activity can be enhanced by calcium 
influx, retinoic acid receptor signaling, PKC signaling, cholesterol depletion, and 
N-glycosylation168-172.  
 Some of the most well characterized ADAM10 substrates are Notch 
receptors. As mentioned earlier, Notch receptors regulate cellular differentiation. 
Following Notch receptor-ligand interaction, including Delta-like 1-4 and Jagged 
1-2, Notch signaling is initiated by ADAM-mediated proteolysis of the 
extracellular domain of the Notch receptor. The extracellular domain is released 
and endocytosed by adjacent ligand-expressing cells. This cleavage event, 
termed S2 cleavage, produces a substrate that can then be cleaved by the γ-
secretase complex (S3 cleavage). Subsequently, the Notch intracellular domain 
(NICD) is released from the cell membrane. NICD then translocates to the 
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nucleus where it complexes with the transcription factor RBP-Jκ and induces the 
transcription of Notch target genes, such as CD21, Hes 1, Hes 5 and deltex-1173. 
Notch1 and Notch2 are the main Notch receptors involved in lymphocyte biology. 
It has been demonstrated that ADAM10 can mediate their cleavage24,174. Notch1 
and Notch2 have been shown to mediate different functions. For example, while 
Notch1 is required for T cell development, Notch2 signaling is necessary for the 
development of marginal zone B cells25,174. These cleavage events are depicted 
in Figure 2B. Recent studies have demonstrated that ADAM10 can also mediate 
trans-cleavage, however, these activity has only been demonstrated for one 
substrate, ephrin, and it is not thought to be ADAM10’s main mechanism of 
action175.  
 Studies have demonstrated that Notch1 signaling is essential for 
commitment to T cell lineage, and given its role in Notch1 signaling, ADAM10 
also plays a key role in T cell development174,176. Moreover, ADAM10 is essential 
for MZ B cell development due to its role in the initiation of Notch2 signaling24,25. 
Notch signaling has been recently implicated in mature B cell activation and 
function. Thomas et al. demonstrated that Notch signaling synergizes with B-cell 
receptor (BCR) and CD40 signaling to enhance B cell activation177. Further 
studies by Santos et al. showed that Notch signaling contributes to B cell 
differentiation into antibody secreting cells (ASC) in vitro and also, under some 
conditions, promotes class switching178 In addition to B-cell activation and 
differentiation into ASCs, Notch signaling has also been implicated in GC 
formation. Yoon et al. recently demonstrated that Notch signaling protects GC B 
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cells from apoptosis. These reports demonstrate the importance of Notch 
signaling in regulating B cell survival, activation, and differentiation into ASCs179.  
These studies failed to determine whether the results observed were due to 
Notch1 or Notch2 activation. Moreover, these results were obtained through in 
vitro studies that might not represent in vivo biology. Interestingly, B-cell specific 
RBP-Jκ deficient mice showed no defect in T-dependent or T-independent 
antibody responses180, thus suggesting that Notch signaling might affect B cell 
terminal differentiation in a RBP-Jκ independent-manner, RBP-Jκ deficiency can 
be compensated in vivo or Notch signaling might not be important in vivo.  
 Here we aimed to address the role of ADAM10 in early B cell 
development, in GC formation, and PC development and function. We 
conditionally deleted ADAM10 in B cells at three distinct developmental stages 
and assessed the impact in B cell development and function in each of the 
mouse lines. Our results demonstrate that early deletion of ADAM10, starting at 
the pro/pre-B cell stage (ADAM10Δ/Δmb1-cre+/- mice), does not alter immature B 
cell development. However, consistent with previous work, MZ B cell 
development was impaired24. ADAM10 deletion in mature B cells 
(ADAM10Δ/ΔCD19-cre+/- mice) resulted in a dramatic defect in GC formation and 
antibody responses, accompanied with changes in splenic and LN 
architecture181. On the other hand, deletion of ADAM10 within germinal centers 
(ADAM10Δ/ΔIgG1-cre+/- mice) did not impair GC B cells numbers nor lymphoid 
architecture, but still led to dramatic defects in humoral responses due to altered 
PC gene expression.  
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Table 4. List of Relevant ADAM10 substrates 
Substrate Function Reference 
CD23 Low affinity IgE receptor; Important for 
regulating IgE production 
182 
IL-6 
Receptor 
Ubiquitously expressed; Involved in pro-
inflammatory responses 
183 
Notch 
Receptors 
Important for cell differentiation 24,174 
CXCL16 Chemokine produced by dendritic cells in T cell 
area of secondary lymphoid tissues 
184 
TNF-α Pro-inflammatory cytokine, also involved in 
lymphoid tissue development 
185 
Fas Ligand 
(CD95L) 
Cytokine involved in cell death; interacts with 
Fas 
186 
CD40 
Ligand 
Protein important for B cell activation. T cell 
expressed. 
187 
RANK 
Ligand 
Important for dendritic cell maturation, LN 
development and osteogenesis 
188 
CX3CL1 Important for leukocyte migration 189 
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Figure 2. ADAM structure.  
ADAMs are composed of multiple domains, as depicted in this figure.  
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Figure 3. Notch signaling 
ADAM10-mediated RIP of Notch2 is required for MZ B cell development25. The 
Notch2 heterodimer on B cells binds ligands, Jagged 1–2 and Delta-like 1, 
present on stromal and antigen presenting cells. Binding initiates sequential 
cleavage events by ADAM10 (S2 cleavage) and γ-secretase complex (S3 
cleavage). Cleavage releases the Notch2 intracellular domain (N2ICD). 
Transport of the N2ICD to the nucleus followed by binding to the transcription 
factor RBP-Jκ allows the release of co-repressors (CoR) and attraction of co-
activators (CoA) to the transcriptional complex. The activated complex 
transcribes Notch target genes, including CD21/35, Deltex-1, Hes 1, and Hes 5, 
that promote development of MZ B cells. Deletion of ADAM10, Notch2, and RBP-
Jκ from B cells, or Delta-like 1 from stromal cells prevents MZ B cell 
development.  
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esis of multiple disease states, including cancer and inflammation
(Blobel, 2005; Crawford et al., 2009). In particular, the role of
ADAM10-mediated APP processing and its effect on Alzheimer’s
disease have been extensively studied and are reviewed elsewhere
(Postina, 2008). Here, we discuss recent studies that highlight the
physiologic role of ADAM10-mediated cleavage events in lym-
phocyte development and inflammation related to autoimmunity.
Additionally, we review reports describing novel functions of
ADAM10, and the regulation of proteolytic activity.
2. The rate-limiting protease in Notch RIP
2.1. A historical perspective
Since its discovery, it was evident that ADAM10 and its
drosophilahomolog,Kuzbanian (kuz), performcritical roles indevel-
opmental pathways. Kuz was initially identified by Rooke et al.
(1996), who generated kuz− embryos that revealed its essential
role in lateral inhibition required for development of peripheral
and central nervous systems. Cloning and sequence analysis of
kuz demonstrated the presence of disintegrin and metallopro-
teinase domains (Rooke et al., 1996). Database searches identified
a mammalian homolog (43% amino acid identity), bovine metal-
loprotease (BMP, later named ADAM10 (Wolfsberg et al., 1995))
that was isolated from brain myelin and shown to cleave myelin
basic protein in vitro (Howard and Glynn, 1995). By overexpress-
ing dominant negative (DN) mutants of kuz that lack the protease
domain in drosophila and Xenopus, Pan and Rubin (1997) demon-
strated that thedefect in lateral inhibition is due to the requirement
for kuz to initiate RIP-mediated signaling through the Notch recep-
tor. This finding was supported by Sotillos et al. However, the
authors acknowledged phenotypic differences between kuz and
Notchmutantfliesandconcluded thatNotch couldalsobeprocessed
in a kuz-independent manner (Sotillos et al., 1997).
In mammalian cells, signaling through Notch receptors criti-
cally regulates cell fate processes of numerous cell types, including
murine embryos. Following receptor ligation of Notch ligands,
includingDelta-like (Dll)1-4 and Jagged 1–2, expressed on adjacent
cells, Notch signaling is initiated by ADAM-mediated proteolysis of
the extracellular domain of the Notch receptor that is endocytosed
by the ligand-expressing cell. This cleavage event, termed the S2
cleavage, produces a substrate for the !-secretase complex to per-
formS3 cleavage and release theNotch intracellular domain (NICD)
from the cell membrane. This results in NICD translocation to the
nucleus, where it complexes with the transcription factor RBP-J",
and induces transcription of Notch target genes, including Hairy
enhancer of split (Hes1), Hes5, and Deltex-1 (Fig. 1).
Although numerous regulators of Notch signaling have been
identified, the identity of the metalloprotease that initiates
RIP-mediated Notch signaling in mammalian cells was highly
controversial (Kopan and Ilagan, 2009). Initially, two indepen-
dent groups concluded that ADAM17 (TNF-# converting enzyme,
TACE) initiates signaling by performing S2 cleavage of the Notch1
receptor (Brou et al., 2000; Mumm et al., 2000). Loading cell mem-
brane fragments from Notch-transfected HeLa cells onto RED-TSK
columns resulted in co-elution of Notch receptor cleavage prod-
uctswith ADAM17, rather thanADAM10. Additionally, results of an
in vitro cleavage assay and a monocytic cell differentiation exper-
iment demonstrated ADAM17’s ability to cleave truncated forms
of Notch1 and direct Notch-dependent monocyte differentiation
(Brou et al., 2000). Mumm et al. (2000) supported this finding by
demonstrating Notch cleavage in transfected MEFs derived from
ADAM10-null embryos. As a result, ADAM17 is often referenced
in the literature as the relevant proteinase that initiates Notch
signaling (Radtke et al., 2004). Although these findings were in
Fig. 1. ADAM10-mediated RIP of Notch2 is required for Marginal Zone B cell devel-
opment. Signaling through the Notch2 receptor expressed on transitional B cells
directs marginal zone B cell differentiation (Saito et al., 2003). The Notch2 het-
erodimeronBcellsbinds ligands, Jagged1–2andDelta-like1,presentonstromaland
antigenpresentingcells. Binding initiates sequential cleavageeventsbyADAM10(S2
cleavage) and a !-secretase complex (S3 cleavage). Cleavage releases the Notch2
intracellular domain (N2ICD), containing RAM , nuclear localization , transac-
tivating (TAD) , EGF-repeat , and PEST domains . Transport of the N2ICD
to the nucleus followed by binding to the transcription factor, RBP-J", allows the
release of co-repressors (CoR), and attraction of co-activators (CoA) to the transcrip-
tional complex. The activated complex transcribes Notch target genes, including
CD21/35, Deltex-1, Hes 1, and Hes 5, that promote development of marginal zone
B cells. Deletion of ADAM10, Notch2, and RBP-J" from B cells, or Delta-like 1 from
stromal cells prevents marginal zone B cell development.
direct contrast to studies of kuz in drosophila, the authors could
not rule out a role for ADAM10 in Notch cleavage, and suggested
that ADAM10 and ADAM17may be functionally redundant in vivo.
This conclusion was supported by later in vitro studies demon-
strating that ADAM10 can cleave many ADAM17 substrates from
ADAM17−/− MEFs (Le Gall et al., 2009), while ADAM17 can also
cleave numerous ADAM10 substrates (Hinkle et al., 2004; Sahin
et al., 2004). However, a critical role for ADAM10 in Notch acti-
vation re-emerged following the generation of ADAM10-deficient
mouse embryos that displayedmany features also observed in non-
viable Notch1−/− embryos (Hartmann et al., 2002; Swiatek et al.,
1994). In contrast, embryonic loss of ADAM17 did not result in a
Notch phenotype (Peschon et al., 1998). Following these observa-
tions, two groups utilizingADAM10−/−MEFs recently reported that
whilemultiple proteases can perform ligand-independent proteol-
ysis of Notch1, ADAM10 is required for ligand-dependent cleavage
of Notch (Bozkulak and Weinmaster, 2009; van Tetering et al.,
2009). Thus, ADAM10may play amore critical role in Notch signal-
ing thanearlier in vitro studiespredicted.However, inutero lethality
of ADAM10-null embryos at day E9.5 had limited the examination
of ADAM10-mediated cleavage events in the development of other
cell types, including lymphocytes.
2.2. T cell development
The impact of Notch signaling in T cell development has been
thoroughly examined, and is reviewed elsewhere (Tanigaki and
Honjo, 2007). Briefly, Notch1 signaling is essential for the devel-
opment of thymocyte precursors. This is best illustrated by the
presence of thymic B cells in mice that lack Notch1 expression in
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3.2 ADAM10 and early B cell development 
ADAM10 expression in early B cell subsets 
 ADAM10 plays a key role in Notch signaling. While it is well established 
that Notch1 signaling is essential for the commitment to T-cell lineage176, whether 
or not ADAM10 plays a role in early B cell development post-lineage commitment 
has not been formally investigated. It has been previously reported that ADAM10 
is expressed in B cell populations within the spleen, including MZBs and FOB 
cells24. In order to further characterize ADAM10 expression in the B cell lineage, 
bone marrow cells were isolated and analyzed by flow cytometry for ADAM10 
surface expression. This study revealed that ADAM10 is expressed in early B cell 
progenitors, including pro-B cells, pre-B cells, and immature B cells (Figure 4). 
This data suggested that ADAM10 might be involved in early B cell development. 
 
Generation of early B cell specific ADAM10 deficient mice 
Our lab has recently generated B cell-specific ADAM10 knockout mice 
(ADAM10Δ/ΔCD19-cre+) by crossing mice with homozygous floxxed ADAM10 
(ADAM10-flox) with CD19-cre animals (CD19-cre+)190. Flow cytometry and 
immunohistochemical analysis revealed that ADAM10Δ/ΔCD19-cre+ lacked 
marginal zone B cells (MZBs), had dramatically reduced numbers of pre-MZBs, 
and a significant increase in follicular B cells (FOB)24.  
 While CD19 expression can be detected starting at the pro-B cell 
stage8, CD19-cre mediates efficient recombination of loxP-flanked genes in 
mature cells and, to a lesser degree, in immature B and pre-B cells (see 
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introduction, section 1.1), leading to recombination in a limited number of bone 
marrow B cells147.  
 Given that cre recombinase is poorly expressed in early B cells when 
under the control of the CD19-promoter, we investigated another B cell specific 
cre mouse line. The mb1-cre mouse line was obtained from the Reth 
laboratory147. The mb1 gene encodes the Igα signaling subunit of the B cell 
receptor191 and it is expressed very early in B cell lineage, beginning at the pro-B 
cell stage49. Couple to Igβ, it facilitates antigen binding192. In order to compare 
the level of recombination that occurs in the BM when Cre recombinase is 
expressed under the control of CD19 promoter or mb1 promoter, we took 
advantage of YFP reporter mice. The YFP reporter mouse line expresses YFP 
after cre-mediated recombination. BM cells were isolated from mb1-cre+YFP+ 
and CD19-cre+YFP+ mice. The percentage of CD19+YFP+ B cells was then 
compared between the two lines. Consistent with published results, mb1-cre 
mice showed much more efficient recombination (Figure 5). While nearly all 
CD19+ B cells (98.9%) were YFP+ in BM of mb1-cre+ mice, only 10% of CD19+ B 
cells had undergone cre-mediated recombination in CD19-cre+ mice. These 
results support the concept that CD19-cre mouse models are not well suited for 
the generation early B cell-specific knockout mice.  
 
ADAM10 is dispensable for early B cell development 
 Spleen and BM cells were isolated from 8- to 12- week old 
ADAM10Δ/Δmb1-cre+ animals and control animals (ADAM10Δ/Δmb1-cre- mice). B 
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cell populations were analyzed by flow cytometry. In the BM, the percentage of 
immature B cells, defined as B220+IgM+ and pro/pre-B cells, defined as 
B220+IgM-, was comparable between ADAM10Δ/Δmb1-cre+/- and WT controls 
(Figure 6). Consistent with this finding, recently published work demonstrated 
that B cells developed normally in the presence of ADAM10-inhibitors in an in 
vitro model of hematopoiesis193. These results demonstrate that ADAM10 is 
dispensable for early B cell development. Consistent with previously published 
results, ADAM10Δ/Δmb1-cre+/- mice lacked MZ B cells in the spleen (Figure 7) 
(MZ B cells are described in section 1.2)24.  
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Figure 4. ADAM10 expression in bone marrow B cells.   
Bone marrow derived cells isolated from C57BL/6 mice were stained for B220, 
IgM, CD43, and ADAM10. B cell subsets were defined as follows: Pro-B cells: 
B220+CD43+IgM-; Pre-B: B220+CD43-IgM+; and immature B cell: B220+IgM+.Blue 
represents sample while gray represent isotype control. MFI; mean fluorescent 
intensity. Experiment was carried out 3 times with similar results. Two mice of 
each genotype per experiment.  
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Figure 5. Comparison of recombination efficiency between mb1-cre and 
CD19-cre mouse models.  
Bone marrow cells from CD19-cre+YFP+ or mb-1-cre+YFP+ mice were stained for 
CD19 and analyzed by flow cytometry. The percentage of CD19+YFP+ is 
displayed in the upper right quadrant of each FACS plot.  
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Figure 6. ADAM10 is dispensable for early B cell development.  
Bone marrow cells were isolated from ADAM10Δ/Δmb1-cre+/- and WT mice and 
analyzed via flow cytometry for immature (B220+IgM+) and pro/pre-B cells 
(B220+IgM-). Representative contour plots are shown. Experiment was carried 
out 3 times with similar results. Two mice of each genotype per experiment. 
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Figure 7. ADAM10 is required for marginal zone B cell development.  
Spleen cells were isolated from ADAM10Δ/Δmb1-cre+/- and WT mice and 
analyzed via flow cytometry for follicular (B220+CD23hiCD21/35+IgM+) (blue) and 
pre-MZB (B220+CD23hiCD21/35hiIgMhi) (red) [top] and marginal zone B cells 
(B220+CD23loCD21/35hiIgM+) [bottom]. Representative contour plots are shown.  
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3.3 ADAM10 is essential for Germinal Center formation and maintenance of 
lymphoid architecture 
ADAM10 is highly expressed in GC B cells  
 ADAM10 cleaves a variety of substrates that have been associated with 
humoral responses, such as TNF-α, Notch1, Notch2, and CD23174,182,185. We 
therefore sought to determine the role of ADAM10 in GC formation and antibody 
production. Delineation of ADAM10 expression patterns in B cells is an important 
step toward understanding the potential role of the proteinase in humoral 
immunity. Flow cytometry analysis demonstrated that within Peyer’s patches, 
while less than 2% of naïve B cells expressed ADAM10, over 80% of GC B cells 
were ADAM10+ (Figure 8A,B). The flow cytometry results were confirmed by 
immunohistochemistry of Peyer’s patches stained for ADAM10, PNA, and IgD. 
Consistent with our flow cytometry results, ADAM10 was highly expressed by 
cells within GCs  (Figure 8C). Peyer’s patches were chosen due to the expected 
high level of GC activation. 
 
Humoral immune responses in ADAM10B-/- deficient mice 
  Given the significant expression of ADAM10 in GC B cells, we 
investigated its role in humoral responses by using B cell specific ADAM10-
deficient mice (ADAM10B-/-). Basal levels of serum IgM, IgG1, IgG2a, and IgG2b 
were significantly reduced in ADAM10B-/- mice when compared to WT, suggesting 
a defect in antibody production (Figure 9A). To directly assess antigen-specific 
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antibody production, ADAM10B-/- mice were immunized i.p. with NP-KLH, and 
serum levels of NP-specific antibodies were examined. ADAM10B-/- mice showed 
reduced levels of NP-specific IgM 7 days post-immunization. However, levels 
reached WT values by day 21 and through the remainder of the experiment 
(Figure 9B). In contrast, NP-specific IgG levels, both total and high affinity, were 
reduced for 4 weeks post-immunization (Figure 9B).  This reduction in IgG was 
not specific to a particular isotype, as antigen-specific IgG1, IgG2a, and IgG2b 
were dramatically reduced in ADAM10B-/- mice (Figure 10A). Furthermore, even 
when immunized with a high antigen dose of 1mg of NP-KLH, ADAM10B-/- mice 
failed to mount a normal antibody response. This result demonstrates that the 
defect in antibody production cannot be overcome by simply providing more 
antigen (Figure 10B).  
 To test if memory responses were also impaired in ADAM10B-/- mice, WT 
controls and ADAM10B-/- mice were immunized and boosted 42 days later. 
Consistent with data shown in Figure 8B, ADAM10B-/- mice had decreased levels 
of antigen-specific antibodies after primary immunization. Moreover, while WT 
controls exhibited a 12-fold increase in anti-NP IgG antibodies 5 days after 
secondary immunization (from 38.34 +/- 25 to 461.5 +/- 72.45), ADAM10B-/- mice 
only had a 4-fold increase (from 3.133 +/- 2.888 to 12.36 +/- 6.4460). 
Furthermore, 5 days after boost, WT mice produced 16 times more high affinity 
antigen-specific IgG and 37 times more total NP-specific IgG than ADAM10B-/- 
mice (Figure 9C). These results demonstrate that in ADAM10B-/- mice both 
primary and recall antibody responses are impaired. 
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Fewer NP-specific Antibody Secreting Cells are observed in ADAM10B-/- mice 
 Given the severe defect in antibody production observed in ADAM10B-/-, 
mice we hypothesized that the generation of antigen-specific PCs was impaired.  
Examination of antibody secreting cells (ASCs) by ELISPOT assays showed that 
immunized ADAM10B-/- mice had drastically reduced numbers of NP-specific 
ASCs in the spleens and BM 21 days post-immunization (Figure 11A,B). Similar 
results were observed in spleens 14 and 28 days after immunization 
(Figure11D,E). Together, these results demonstrate that the decrease in splenic 
ASCs is not due to altered migration or preferential localization to the BM, but 
likely due to impairments in PC differentiation and/or survival.  
 A critical component of the humoral response is affinity maturation. Thus, 
we next examined affinity maturation in immunized ADAM10B-/- mice. While 21 
days after immunization most ASCs were secreting high affinity antibodies in WT 
controls, the few ASCs that were present in ADAM10B-/- mice were secreting low 
affinity Ab. WT controls had 12-fold higher number of NP-specific ASCs and 20-
fold higher number of NP-specific ASCs producing high affinity antibodies when 
compared to ADAM10B-/- mice. Moreover, when the ratio of high affinity and total 
ASCs was calculated, it was evident that the generation of high affinity ASCs in 
ADAM10B-/- mice was especially affected (Figure 11C). These results suggest a 
defect in affinity maturation in ADAM10B-/- mice. 
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GC formation is impaired in ADAM10B-/- mice 
 As demonstrated in Figure 10, that antigen-specific ASCs were reduced in 
immunized ADAM10B-/- mice. Being that long-lived PCs and memory cells are 
generated within GCs31, GC formation in ADAM10B-/- mice was examined. GC B 
cells, defined as IgMloIgDloB220+IgG1+CD38lo were enumerated by flow 
cytometry194 (Figure 12A). Remarkably, the number and percentage of GC B 
cells within the spleen was dramatically decreased in ADAM10B-/- mice (Figure 
12B,C). Similar results were obtained when GC B cells were defined as 
B220+GL7+Fashi (Figure 12D). Activation induced cytosine deaminase (AID) is 
essential for SHM and CSR, two events that occur within GCs80,195. Therefore, 
consistent with a decrease in the number of GC B cells, AID expression was also 
decreased in draining LN of ADAM10B-/- mice compared to that of WT (Figure 
13).  
 
ADAM10B-/- mice have altered splenic and lymph node architecture 
 In order to better understand the relationship between decreased GC B 
cells and the defects in antibody production observed, GC formation in 
immunized mice was assessed by immunohistochemistry. As depicted in Figure 
14A, while several GCs could be detected in WT controls, as determined by GL-
7+ positive cells, draining LN of ADAM10B-/- mice contained a paucity of GL7+ 
clusters. Interestingly, GL7+ cells were scattered throughout the LN of ADAM10B-
/- mice (Figure 14A). Given the unusual pattern of GL-7 expression, we analyzed 
B- and T cell localization within the LN. Surprisingly, the distribution of B cells 
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and T cells was aberrant, suggesting that B cell specific ADAM10 deletion leads 
to changes in LN structure (Figure 14B).  In contrast, LN structure in non-draining 
nodes or unimmunized mice was normal with regards to B- and T cell 
segregation. However, B cell follicles appeared thin, reminiscent of TNF-α and 
LTβ- deficient mice (Figure 14D)14,196. 
 Given that FDCs play a crucial role in GC formation and lymphoid tissue 
structure18,197,198, we stained draining LN sections for FDC with CD21/35 (CR2). 
FDCs are known to upregulate CD21/35 subsequent to activation199. Consistent 
with an absence in GCs and disorganized lymphoid architecture, FDC networks 
were not detected in LN and spleen from ADAM10B-/- mice (Figure 14C, Figure 
15D). Unlike the draining LN, GL7 staining was not detected in spleen of 
ADAM10B-/- mice  (Figure 15A). However, although normal in unimmunized mice, 
splenic architecture was also clearly altered post-immunization (Figure 15B,C). 
   
ADAM10B-/- mice have dysregulated chemokine expression following antigen 
challenge 
 The organization of secondary lymphoid tissues is highly regulated by 
chemokine gradients. To determine if the changes in structure observed were 
accompanied by altered chemokine expression, chemokine expression in 
draining and non-draining LN was assessed by qPCR. As expected, non-draining 
LN from WT and ADAM10B-/- mice had similar CXCL13, CCL19 and CCL21 
expression (Figure 16A). In sharp contrast, draining LN isolated from ADAM10B-/- 
mice exhibited increased CCL21 expression, while CXCL13 levels were 
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comparable. CCL19 levels trended higher, but the increase was not statistically 
significant (Figure 16B). Analysis of CCL21 expression by immunohistochemistry 
revealed an expanded area of CCL21 staining in the ADAM10B-/- LN (Figure 
16C), consistent with the localization of T cells within draining lymph nodes 
(Figure 14B). These results demonstrate that B cell expressed ADAM10 is 
important for maintenance of lymphoid architecture and regulation of chemokine 
expression during active immune responses.  
 Despite having normal levels CXCL13 expression, ADAM10B-/- showed an 
abnormal pattern of B-cell localization secondary to antigen challenge. We 
therefore decided to investigate whether ADAM10-deficient B cells showed 
altered migration to the B cell chemoattractants, CXCL13 and CXCL12. 
Interestingly, ADAM10-deficient B cells showed enhanced migration to CXCL13, 
but not CXCL12 (Figure 17), despite having normal receptor expression (Figure 
18). 
  
B cell specific ADAM10 deletion leads to structural changes in naïve LN 
 Given the abnormal appearance of B cell follicles in LN isolated from 
ADAM10B-/- mice, we decided to look at other features of lymph node 
architecture, such as collagen deposition and stromal cell populations. While 
collagen is heavily deposited within the T-cell zone of lymph nodes, B cell 
follicles seem to have very few collagen fibers200. As depicted in Figure 19, LN 
isolated from ADAM10B-/- showed excessive collagen deposition when compared 
to WT LN. Where in WT LN, B cell follicles showed sparse collagen deposition, 
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collagen was detected throughout the LN of ADAM10B-/- mice. ADAM10 has been 
demonstrated to have collagenase capacity201, so it is possible that B cell 
expressed ADAM10 is required for collagen breakdown within B cell follicles; 
therefore, in the absence of ADAM10, collagen deposition is increased. These 
results are consistent with abnormal LN development.  
 There are several subsets of stromal cells present in LN. They are CD45-, 
as they are not of hematopoietic origin, and can be further divided into four 
categories based on their expression of CD31 and gp38, also known as 
podoplanin or pdp. Fibroblastic reticular cells (FRCs) are defined as gp38+CD31-; 
lymph endothelial cells (LECs) are defined as gp38+CD31+ and blood endothelial 
cells (BECs) are defined as gp38-CD31+. gp38-CD31- cells are a heterogeneous 
population of stromal cells–FDCs are thought to be represented in this 
population19. The FRC subset is mostly composed of T cell zone reticular cells, 
also referred to TRCs. These are the cells responsible for producing CCL21 and 
CCL19, and thus, for the regulation of T cell homing19. Given the increase in 
CCL21 and CCL19 in draining LN from ADAM10B-/- and the thinning of the B cell 
follicles, we hypothesized that LNs from ADAM10B-/- would have increased FRC 
numbers. Indeed, there was a relative increase in FRCs in LN from aged 
ADAM10B-/- (16-20 weeks) (Figure 20). Interestingly, when the experiment was 
repeated with young mice 4 weeks of age, there was a reduction in the 
proportion of FRCs and an increase in BECs (Figure 21). These results 
demonstrate that ADAM10 deletion from B cells leads to loss of FDCs as well as 
alterations in the FRC compartment. 
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ADAM10-deficient B cells secrete less TNF-α following in vitro stimulation 
 As previously mentioned, the LN appearance of ADAM10B-/- mice was 
similar to that of TNF-α deficient mice. Being that ADAM10 has been shown to 
cleave TNF-α and that B-cell TNF-α is important for lymphoid tissue 
development185,202, we sought to determine whether ADAM10-deficient B cell 
produce less TNF-α following activation. Indeed, studies showed that subsequent 
to LPS stimulation a significantly decreased amount of TNF-α could be detected 
in supernatant of ADAM10-deficient B cells, despite normal TNF-α mRNA 
expression (Figure 22). Further studies are needed to determine whether 
decrease TNF-α release is the mechanism underlying the changes in 
architecture and defects in humoral responses observed in ADAM10B-/- mice.  
 
Defect in humoral responses in ADAM10B-/- mice is Notch2 and CD23-
independent. 
 Recent studies have suggested that Notch signaling was involved in 
antibody production and ASC differentiation177,178. ADAM10 is critical for the 
initiation of Notch signaling. To determine if the antibody production defects were 
due to impaired Notch signaling, we generated mice that lack ADAM10 and have 
constitutively active Notch2 signaling in a B cell specific manner (ADAM10B-/-
N2ICD-TgB+). As expected, expression of N2ICD recovered MZ B cell 
development in these mice, demonstrating that the transgene was indeed active 
(Figure 23A). WT, ADAM10B-/- and ADAM10B-/-N2ICD-TgB+ mice were 
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immunized. Consistent with previous experiments, ADAM10B-/- mice had 
significantly reduced levels of NP-specific antibodies. Importantly, introduction of 
N2ICD transgene failed to rescue the defect in antibody production and GC 
formation. Moreover, it did not prevent changes in LN architecture (Figure 
23B,C). These results demonstrate that increased Notch signaling cannot rescue 
the defects in humoral responses.  
 We have recently reported that ADAM10 is responsible for the cleavage of 
the low affinity IgE receptor, CD23182, and consequently, ADAM10-deficient B 
cells have increased CD23 expression24,123. Studies have revealed that CD23 
overexpression leads to decreased IgG1 and IgE production55,145. However, 
when CD23Tg mice were immunized with NP-KLH, analysis of NP-specific IgG 
levels indicated that CD23Tg mice had a normal antibody response to NP-KLH 
(Figure 24). Furthermore, it has been previously reported that CD23Tg mice form 
GCs following immunization with T-dependent antigens. It should be noted that 
the GCs observed in CD23Tg mice had a more globular appearance than WT203. 
These results suggest that the humoral defect observed in ADAM10B-/- mice is 
not secondary to CD23 overexpression, however, this should be more carefully 
addressed. Another relevant ADAM10 substrate is CXC3CL1 (see below).  
 
CX3CR1 deficient mice have enhanced humoral responses 
 Another ADAM10 substrate is CX3CL1, also known as fractalkine in 
humans and neurotactin in mice204,205. CX3CL1 mediates its function through 
binding to its receptor CX3CR168,70,148. CX3CL1 is a chemokine that exists in two 
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forms; the membrane bound form mediates leukocyte adhesion, while the soluble 
for acts as a conventional chemokine, attracting monocytes, NK cells, T cells and 
B cells125,206,207.  Recent studies have suggested a role of CX3CR1/CX3CL1 
signaling axis in GC formation and antibody responses. Studies have 
demonstrated that GC B cells migrate to CX3CL134,208. Moreover, it has been 
suggested that TFH and FDCs secrete CX3CL1 and that through this mechanism, 
they promote GC B cell survival35,207. Interestingly, CX3CR1-deficient mice 
showed decreased basal levels of IgM but increased IgG1 levels (Figure 25). 
These results suggest enhanced class switch recombination.  
 Given that CX3CR1-deficient mice had altered basal antibody levels, we 
decided to assess antigen specific antibody responses. To this end, WT and 
CX3CR1-deficient mice were immunized the NP-KLH and GC formation and 
antibody production were determined. Despite having a slight, but statistically 
significant decrease in the percentage of GC B cells, CX3CR1-deficient mice had 
an enhanced antibody response to NP-KLH immunization (Figure 26). Further 
studies will be required in order to elucidate the mechanism undelaying this 
phenotype. 
 
Antibody production in ADAM10B-/- mice can be partially rescued by repeated 
immunization  
 Very often, murine immunization protocols involve an initial immunization 
and a challenge two weeks later. When this immunization schedule was carried 
out with ADAM10B-/- mice, we were surprised to see that total NP-specific IgG 
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levels were similar between WT and ADAM10B-/- mice. On the other hand, high 
affinity NP-specific IgG levels were still significantly lower following the boost 
(Figure 27A). Similar results were obtained when NP-specific PCs were 
quantified by ELISPOT (Figure 27B). Immunohistochemistry analysis should be 
carried out in this system in order to determine whether repeated immunization 
rescues GC formation and changes in architecture.  
 A key difference between a primary immunization and secondary 
immunization is the presence of pre-existing antibodies and the formation of 
immunine complexes. Given that antibody production was partially rescued by 
repeated immunization, we hypothesized that the antibody defects observed in 
ADAM10B-/- mice could be rescued by immunization with immune complexes. WT 
and ADAM10B-/- mice were immunized with NP-OVA or NP-OVA and anti-OVA 
antibodies (IC). Mice were bled five days later and the presence of NP-specific 
IgM and IgG1 was assessed by ELISA. Surprisingly, WT mice, whether they 
received antigen alone or immune complexes produced significantly more NP-
specific IgM than ADAM10B-/- mice (Figure 28A). Regarding NP-specific IgG1, 
levels were only detectable in WT mice that received immune complexes. In 
ADAM10B-/- mice, NP-specific IgG1 was not detected in either group (Figure 
28B). These results demonstrate that immunization with immune complexes 
does not rescue antibody production defect. However, it is possible that if mice 
were analyzed at a later time point, antibody production might be restored to WT 
levels, thus suggesting a kinetics defect.  
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Defective antibody production seen in ADAM10B-/- mice might be explained by 
decreased B cell help 
 We have demonstrated that ADAM10B-/- mice have impaired antibody 
responses to T-dependent antigens as well as changes in splenic and LN 
architecture. In order to assess whether the decreased antibody levels result 
from a B cell intrinsic defect, splenocytes were stimulated with CD40L and IL-4 in 
vitro. Interestingly, WT and ADAM10-null B cells made comparable amounts of 
IgG1 (Figure 29A) demonstrating that when adequately stimulated, ADAM10-null 
B cells are able to class switch normally.  
 TFH cells provide B cell help via CD40L, IL-21 and IL-4 and play important 
roles in GC B cell survival, affinity maturation and terminal differentiation to 
PCs51,52,209,210. TFH cells are characterized by high expression of CXCR5 and PD-
1, and IL-21 production210. Given our in vitro findings and the changes in 
architecture observed in ADAM10B-/- mice, we hypothesized that the defects in 
humoral responses observed resulted from inadequate B cell stimulation and 
decreased T cell help. Results revealed that TFH development and/or 
maintenance was impaired in ADAM10B-/- mice, as fewer TFH cells were present 
in draining lymph nodes of ADAM10B-/- mice (Figure 29B). Consistent with 
decreased number of TFH cells, IL-21 message levels were also reduced in vivo 
(Figure 29C). These results demonstrate that while ADAM10 deficient B cells can 
produce normal levels of antibody in vitro when stimulated with anti-CD40 and IL-
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4, they are unable to class switch efficiently in vivo likely due to decreased T cell 
help.  
 Surprisingly, when ADAM10-deficient B cells were stimulated in vitro with 
LPS, they failed to produce normal antibody levels despite normal proliferations 
(Figure 30). These results demonstrate that ADAM10-deficient B cells respond 
differently to different types of stimuli. Moreover, in vitro stimulation is very 
different from in vivo B cell stimulation and it has been reported to yield different 
results regarding PC differentiation72,135. Therefore, the role of ADAM10 in PC 
differentiation and function warranted a more careful evaluation. ADAM10 
regulation of PC function will be discussed in section 3.4.  
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Figure 8. ADAM10 expression on GC B cells.  
(A-B) Expression of ADAM10 on gated germinal center PNAhi IgDlo (blue) and 
naive PNAloIgDhi (red) B (CD19+) cells isolated from Peyer’s patches. Flow 
cytometry gates used to define the germinal center and naïve B cell populations 
are indicated in left. To demonstrate specificity of staining, an isotype-matched 
monoclonal antibody was used (isotype). (A) Gating protocol is shown. (B) 
Percentage of ADAM10+ cells in naive and GC B cells. (C) Frozen serial sections 
of Peyer’s patches were stained to detect B cell follicles (B220+, blue), germinal 
centers (PNA+, green) and ADAM10 (red) (right panel). To demonstrate 
specificity of staining, isotype-matched mAb were used instead of mAb against 
ADAM10 (left panel). Original magnification: x20. The mucosal epithelium (E) 
also reacts with PNA and anti-ADAM10. Figure courtesy of Joanna Cichy,from 
Jagiellonian University, Krakow, Poland. 
. 
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Figure 9. ADAM10B-/- mice have impaired humoral responses.  
(A) Serum IgM, IgG1, IgG2a and IgG2b were measured by ELISA from non-
manipulated 8-12 week old mice. (B) ADAM10B-/- mice and WT controls were 
immunized with 10µg NP-KLH emulsified in alum. At the indicated times, serum 
samples were collected and total NP-specific IgM, total IgG and high affinity IgG 
antibody titers were determined by ELISA with NP14BSA as capture antigen for 
total and NP4BSA for high affinity ELISA. (C) Mice were immunized with NP-KLH 
emulsified in alum, rested for 42 days, and boosted with 10µg NP-KLH for 5 
days. Mice were bled weekly throughout the course of the experiment. Total and 
high affinity IgG levels were measured by ELISA at each time point. The relative 
unit (RU) values for alum-injected mice were less than 0.001. Bars represent the 
mean ± SE of 5-9 mice per group (*p < 0.05, **p<0.01, ***p<0.001). Data 
represent results obtained in at least two independent experiments. 
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Figure 10. Decreased NP-specific IgG secretion is not IgG subset and 
cannot be overcome by high antigen dose  
(A) ADAM10B-/- mice and WT controls were immunized with NP-KLH emulsified 
in alum. Twenty-eight days after primary immunization, samples were collected 
and NP-specific IgG1, IgG2a and IgG2b antibody titers were determined by 
ELISA with NP14BSA as capture antigen. (B) ADAM10B-/- and WT controls were 
immunized i.p. with 1mg of NP-KLH emulsified in alum. Samples were collected 
at the indicated time post immunization and NP-specific antibodies were 
measured. The relative unit (RU) values for alum-injected mice were less than 
0.001. Bars represent the mean ± SEM of 5 mice per group. Data represent 
results obtained in two independent experiments. (*p<0.05, **p<0.01, ***p<0.001) 
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Figure 11. ADAM10B-/- mice have decreased number of antigen specific 
ASCs.  
ELISPOT analysis of cells producing (A) total (both low and high affinity), (B) 
high-affinity NP-specific IgG and (C) high versus total ratio present in spleen (top) 
and bone marrow (bottom) isolated from WT and ADAM10B-/- mice 21 days post-
immunization with NP-KLH emulsified in alum. (D-E) ELISPOT analysis of cells in 
spleen producing (D) total and (E) high affinity NP-specific IgG 14 and 28 days 
post-immunization.  (*p <0.05, **p<0.01, ***p <0.001). Bars represent the mean 6 
SE of five mice per group. Data represent results obtained in two independent 
experiments. 
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Figure 12. GC formation development following immunization  
ADAM10B-/- and WT mice were immunized with 10 µg NP-KLH emulsified in 
alum. Fourteen and twenty one days post immunization flow cytometry was 
carried out and the presence of GC B cells (IgMloIgDloB220+IgG1+CD38-) in 
spleen was assessed. Staining protocol is depicted (A). Both percentage (B) and 
total number (C) of GCs were enumerated. (D) Mice were immunized as in A-C. 
GC B cells were quantified by flow cytometry as B220+GL7+Fashi fourteen days 
post-immunization. (*p<0.05, **p<0.01). Bars represent the mean ± SE of 3-8 
mice per group.   Data are representative of 3 independent experiments. 
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Figure 13. Aidca expression in draining lymph nodes.  
Mice were immunized in the footpad with 10µg of NP-KLH. Fourteen days after 
immunization, draining LN were isolated and Aidca expression was analyzed by 
qPCR. Bars represent the mean ± SE of 8 mice per group. Data are 
representative of 2 independent experiments. 
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Figure 14. Immunohistochemistry analysis of GC formation and lymph 
node architecture following T-dependent immunization.  
ADAM10B-/- and WT mice were immunized with 10µg NP-KLH emulsified in alum. 
Fourteen days after immunization, draining LN were sectioned and stained for 
(A) GL7 (green) and IgD (red); (B) Thy1.2 (green) and B220 (red); (C) CD21/35 
(green) and B220 (red). (D) non-draining LN were also stained with CD3 (green) 
and B220 (red). Pictures are representative of 3 independent experiments. 
Magnification displayed is 20x. 
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Figure 15. Immunohistochemistry analysis of GC formation and splenic 
architecture following T-dependent immunization.  
ADAM10B-/-  and WT mice were immunized with 10µg NP-KLH emulsified in alum. 
Fourteen days after NP-KLH immunization, spleens were isolated and sectioned.  
Sections stained for (A) GL7 (green) and IgD (red) or (C) Thy 1.2 (green) and 
B220 (red) or (D) B220 (red) and CD21/35 (green). (B) Spleens isolated from 
naïve animals, sectioned and stained for Thy 1.2 (green) and B220 (red). 
Pictures are representative of 3 independent experiments. Magnification 
displayed is 20x for A and B, and 10x for C and D. 
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Figure 16. Chemokine expression in draining lymph nodes.  
Mice were immunized in the footpad with 10µg of NP-KLH. Fourteen days after 
immunization, draining and non-draining LN were isolated and chemokine 
expression was analyzed by qPCR for CCL19, CCL21 and CXCL13. Non-
draining (A) and draining (B) LN are shown. (*p<0.05). Bars represent the 
mean ± SE of 8 mice per group. Data are representative of 2 independent 
experiments. (C) Draining LN were stained for CCL21. White line depicts lymph 
node capsule. Pictures are representative of 3 mice per group. 
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Figure 17. ADAM10-deficient B cells show enhanced migration to CXCL13 
but not CXCL12.  
Splenocytes from WT and ADAM10 were isolated and migration was assayed as 
described in methods section. (Top) 1µg/mL of CXCL13; (bottom) 300ng/mL of 
CXCL12. (***p<0.001, 1-way ANOVA with Tukey post-test). Bars represent the 
mean ± SE of 4-6 mice per group. Data are representative of 3 independent 
experiments.  
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Figure 18. ADAM10-deficient B cells have normal CXCR5 expression.  
Splenocytes were isolated and stained for B220 and CXCR5. (A) Histogram 
demonstrating CXCR5 B cells expression in WT (---) and ADAM10-deficient B 
cells (shaded light blue). Isotype control is also depicted (shaded light gray). (B) 
Quantification of mean fluorescence intensity (MFI). Bars represent the 
mean ± SE of 4-6 mice per group. Data are representative of 3 independent 
experiments.  
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Figure 19. Lymph nodes isolated from ADAM10B-/- mice show abnormal 
collagen deposition.  
Lymph nodes were isolated from naïve WT and ADAM10B-/- mice, sectioned and 
stained for collagen type II. Representative pictures are displayed. 
Immunohistochemistry was performed and analyzed by Mohey Eldin El Shikh. 
  
 99 
  
WT ADAM10B-/-
Follicle
 100 
Figure 20. B cell-specific ADAM10 deletion alters stromal cell populations 
in aged mice.  
Naïve LN were isolated from 16-20 week old mice and single cell suspension 
was generated by enzymatic digestion, as described in methods section. Cells 
were stained and stromal cell populations were analyzed. FRCs are gp38+CD31-; 
LECs are gp38+CD31+, BECs are gp38-CD31+. Double negative (DN) cells are 
gp38-CD31-(A) Representative contour plot. (B) quantification. Bars represent the 
mean ± SE of 4-6 mice per group. Red boxes represent populations that are 
different between WT and ADAM10B-/- mice. Data are representative of 3 
independent experiments. (*p<0.05, ***p<0.001). 
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Figure 21. B cell-specific ADAM10 deletion alters stromal cell populations 
in young mice  
Naïve LN were isolated from 4 week old mice and single cell suspension was 
generated by enzymatic digestion, as described in methods section. Cells were 
stained and stromal cell populations were analyzed. FRCs are gp38+CD31-; 
LECs are gp38+CD31+, BECs are gp38-CD31+. Double negative (DN) cells are 
gp38-CD31-(A) Representative contour plot. (B) quantification. Bars represent the 
mean ± SE of 4-6 mice per group. Red boxes represent populations that are 
different between WT and ADAM10B-/- mice. Data are representative of 3 
independent experiments. (*p<0.05, ***p<0.001). 
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Figure 22. ADAM10 deficient B cells secrete reduced amounts of TNF-α 
following LPS stimulation.  
WT and ADAM10-deficient naïve B cells were isolated via magnetic bead 
separation. Cells were stimulated with 10µg/mL of LPS. Three days after 
stimulation (A) supernatant was harvest and TNF-α was measured by ELISA and 
(B) TNF-α mRNA expression was determined by qPCR. Bars represent the mean 
± SE of 6 mice per group. Data represent results obtained in three independent 
experiments. (***p<0.001).  
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Figure 23. Defect in humoral responses in ADAM10B-/- mice seems to be 
Notch2-independent.  
(A) Splenocytes isolated from ADAM10B-/-, ADAM10B-/-N2ICD-TgB+ and WT mice 
were stained with B220, CD23, CD21/35 and IgM. Marginal zone B cells were 
defined as B220+CD23-/loCD21/35hiIgM+. (B) Mice were immunized in the footpad 
with NP-KLH, 14 days later draining LN were isolated and stained for GL7 and 
IgD (top) and Thy1.2 and B220 (bottom). (C) ADAM10B-/-, ADAM10B-/-N2ICD-TgB+ 
and WT mice were immunized i.p. with NP-KLH emulsified in alum. At the 
indicated times, serum samples were collected and total NP-specific IgG was 
determined by ELISA. Bars represent the mean ± SE of 5 mice per group. Data 
represent results obtained in two independent experiments. (*p<0.05, **p<0.01, 
***p<0.001, One-way ANOVA with Turkey post-test). Significance refers to 
ADAM10B-/- compared to WT and ADAM10B-/-N2ICD-TgB+ compared to WT. 
ADAM10B-/- and ADAM10B-/-N2ICD-TgB+ were not different from each other at any 
time point. 
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Figure 24. CD23Tg mice have a normal IgG response to NP-KLH 
CD23Tg and WT mice were immunized with NP-KLH emulsified in alum. At the 
indicated times, serum samples were collected and total NP-specific IgG was 
determined by ELISA. Bars represent the mean ± SE of 8 mice per group. Data 
represent results obtained in two independent experiments. 
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Figure 25. Basal antibody levels in CX3CR1-deficient mice.   
Serum  (A) IgM, and (B) IgG1 were measured by capture ELISA from non-
manipulated 8-12 week old mice. Bars represent the mean ± SE of 9-15 mice per 
group (*p < 0.05). Data represent results obtained in at least two independent 
experiments. 
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Figure 26. CX3CR1-deficient mice have enhanced antibody responses.  
CX3CR1-deficient mice and WT controls were immunized with 10µg NP-KLH 
emulsified in alum. At the indicated times, serum samples were collected and 
total NP-specific  (A) total IgG and (B) high affinity IgG antibody titers were 
determined by ELISA with NP14BSA as capture antigen for total and NP4BSA for 
high affinity ELISA. (C) Mice were immunized with NP-KLH emulsified in alum, 
fourteen days post-immunization spleens were harvested and analyzed for GC B 
cells by flow cytometry. Quantified results are showed. The relative unit (RU) 
values for alum-injected mice were less than 0.001. Bars represent the 
mean ± SE of 3-10 mice per group (*p < 0.05, **p<0.01, ***p<0.001).  
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Figure 27. Repeated immunization can partially rescue antibody production 
defect in ADAM10B-/- mice.  
ADAM10B-/-  and WT mice were immunized with 10µg NP-KLH emulsified in alum. 
Fourteen days after primary immunization, mice were boosted with 10µg NP-KLH 
emulsified in alum. (A) Mice were bled weekly and total and high-affinity NP-
specific IgG levels were measured by ELISA. (B) Twenty-eight days following 
immunization mice were sacrificed and antibody-secreting cells in spleen and 
bone marrow were quantified by ELISPOT. The relative unit (RU) values for 
alum-injected mice were less than 0.001. Bars represent the mean ± SE of 8-10 
mice per group (*p < 0.05, **p<0.01, ***p<0.001). 
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Figure 28. Immunization with immune complexes does not rescue antibody 
production defects seen in ADAM10B-/- mice.  
WT and ADAM10B-/- were passively immunized subcutaneously with 6mg of 
rabbit polyclonal anti-OVA antibodies or PBS. Twelve hours later, mice were 
injected with 10µ of NP-OVA in alum. Six days later, mice were sacrificed and 
cardiac puncture. Antigen-specific (A) IgM and (B) IgG1 were measured by 
ELISA. Bars represent the mean ± SE of 4 mice per group (*p < 0.05, **p<0.01). 
  
 117 
  
WT ADAM10-B-/-
0
2
4
6
8
10 *
N
P-
Sp
ec
ifi
c 
Ig
M
 (R
U
) *
WT ADAM10-B-/-
0.0
0.5
1.0
1.5
**
ns
NP-OVA
NP-OVA-IC
N
P-
Sp
ec
ifi
c 
Ig
G
1 
(R
U
)
A
B
 118 
Figure 29. Normal responses of ADAM10 deficient B cells under T 
dependent stimulation in vitro, but decreased TFH cell numbers in vivo. 
 (A) Splenocytes were cultured (12.5x106 cells/well) with CD40L-transfected 
Chinese hamster ovary (CHO) cells as a B cell stimulant (6x104 cells/well) for 
seven days. Supernatants were then harvested and analyzed for IgG1 
expression by ELISA. (B-D) Mice were immunized with NP-KLH. Fourteen days 
post immunization flow cytometry was carried out and the presence of TFH (B220-
CD4+CXCR5hiPD-1hi) in the spleen of WT and ADAM10B-/- was assessed. (B). 
Staining protocol is depicted. (C). Percentage of TFH out of CD4+ was 
enumerated  (D) Draining lymph nodes were analyzed for IL-21 mRNA by 
quantitative PCR (*p<0.05, **p<0.01). Bars represent the mean ± SE of 6 mice 
per group. Data are representative of 2 independent experiments. 
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Figure 30. ADAM10-deficient B cells produce reduced antibody amounts 
following LPS stimulation.  
Naïve B cells were isolated via magnetic bead separation and stimulated with 
10µg/mL of LPS. Four days following stimulation, supernatant were harvest and 
analyzed for (A) IgM and (B) IgG1 by ELISA. (C) Two days following challenge, 
tritiated thymidine was added to cells. Cells were incubated for 24 hours and then 
harvested. Thymidine incorporation was then measured. (**p<0.01, ***P<0.005). 
Bars represent the mean ± SE of 6 mice per group. Data are representative of at 
least 2 independent experiments. 
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3.4 ADAM10 regulates plasma cell function 
Generation of ADAM10Δ/ΔIgG1+/- 
 Members of the ADAM family regulate a variety of functions, including, but 
not limited to, cell migration, proliferation and adhesion211. We have previously 
generated mice that lacked ADAM10 in all peripheral B cells (ADAM10B-/- mice) 
by crossing a knockin mouse strain containing loxP sites surrounding exon 9 of 
adam10 (ADAM10Δ/Δ) allele with mice expressing Cre recombinase under the 
control of the CD19 promoter24. As discussed in section 3.3, the study of these 
mice demonstrated a severe defect in GC formation and changes in lymphoid 
architecture181. In order to determine whether ADAM10 plays a role in PC 
development or the defects in antibody production observed in ADAM10B-/- were 
secondary to changes in architecture, we crossed ADAM10Δ/Δ with IgG1-cre 
transgenic mice and generated ADAM10Δ/ΔIgG1-cre+/- mice128. Previous studies 
have demonstrated that IgG1-cre transgene shows specificity for GC B cells with 
approximately 75% of GC B cells expressing Cre recombinase. Introduction of 
the IgG1-cre transgene has been shown to affect IgG1 production; therefore, we 
also generated controls that have cre expression but have WT ADAM10 alleles 
(ADAM10+/+IgG1-cre+/- mice). In order to track cells that had undergone cre-
mediated recombination, we crossed ADAM10Δ/ΔIgG1-cre+/- and ADAM10+/+IgG1-
cre+/- mice with R26R-EYFP+ mice, thus, generating ADAM10Δ/ΔIgG1-cre+/-R26R-
EYFP+ (ADAM10Δ/ΔIgG1-cre+/-YFP+) and ADAM10+/+IgG1-cre+/-YFP+ (control) 
mice that express EYFP transgene following cre-mediated recombination24,74-76.  
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Antibody production and GC formation in ADAM10Δ/ΔIgG1-cre+/-YFP+ mice 
 Our previous study demonstrated that ADAM10-deletion in all peripheral B 
cells (ADAM10B-/- mice) led to severe impairments in antibody production, as 
evidenced from decreased antibody responses to T-dependent antigens. 
Moreover, GC formation was severely affected in those mice. Furthermore, TFH 
cell numbers were also diminished in ADAM10B-/- mice181. In order to determine if 
deletion of ADAM10 within GCs affected basal antibody levels, mice were bled 
and IgM, IgG1 and IgE levels were measured by ELISA. As depicted in Figure 
31A-C, there were no differences between ADAM10Δ/ΔIgG1-cre+/-YFP+ and 
controls mice with regards to basal antibody levels.  
 We then examined whether ADAM10 deletion within GCs affected GC 
maintenance and antigen-specific antibody production. ADAM10Δ/ΔIgG1-cre+/-
YFP+ mice and controls were immunized with 10µg of NP-KLH emulsified in 
alum. The number of GC B cells, defined as B220+GL7+Fashi, 14 days post-
immunization was quantified by flow cytometry. The percentage of GC B cells 
was comparable between ADAM10Δ/ΔIgG1-cre+/-YFP+ and controls (Figure 31D-
E). Immunohistochemistry analysis also showed normal GCs, defined as clusters 
of GL7+ within B cell follicle  and normal splenic follicle architecture (Figure 31F). 
Furthermore, TFH numbers were also normal (Figure 31G).  
 Interestingly, despite normal GC B cell numbers, antigen specific IgG1 
was severely diminished (Figure 32B), while antigen-specific IgM levels were 
comparable to control mice (Figure 32A). The normal IgM levels were not 
surprising, as it has been reported that less that 2% of IgM+ cells undergo cre-
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mediated recombination128. These results demonstrate a defect in class-switched 
antibody production. 
 Mice were also immunized with 100µg of NP-LPS, a T-independent 
antigen. Surprisingly, antibody responses to these antigens were also severely 
impaired (Figure 33). These results are rather unexpected because cre-
expression has been shown to occur in only 7% of IgG3-expressing cells128. 
Further experiments will be needed in order to determine ADAM10-deletion in 
IgG3-expressing cells in our system. Our results seem to suggest that the 
majority of IgG3 secreting cells are ADAM10-deficient, as IgG3 production in 
ADAM10Δ/ΔIgG1-cre+/-YFP+ mice is so dramatically impaired.  
 
Plasma cell development in ADAM10Δ/ΔIgG1-cre+/-YFP+ mice 
 Given that ADAM10Δ/ΔIgG1-cre+/-YFP+ mice had impaired antibody 
responses but normal GCs, we hypothesized that the defect resulted from 
aberrant plasmablast and PC differentiation. CD138 is a marker for antibody-
secreting plasmablast and PCs (B220int/lowCD138+ cells). Accordingly, we 
immunized ADAM10Δ/ΔIgG1-cre+/-YFP+ and ADAM10+/+IgG1-cre+/-YFP+ mice with 
10µg of NP-KLH and determined the percentage of cre-expressed plasmablast 
and PCs (B220int/lowCD138+YFP+ cells) in the spleen (Figure 34B), peripheral 
blood (Figure 34C) and bone marrow (Figure 34D)132. The gating protocol is 
depicted in Figure 34A. Surprisingly, even though ADAM10Δ/ΔIgG1-cre+/-YFP+ 
mice had markedly impaired antigen-specific IgG1 responses, they had 
plasmablast and PC percentages comparable to that of controls. Interestingly, 
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the number of IgG1 expressing cells in the spleen of ADAM10Δ/ΔIgG1-cre+/-YFP+ 
was significantly reduced (Figure 35). These results suggest that either ADAM10-
deletion impairs class switching to IgG1 or more likely, ADAM10-deletion leads to 
impaired antibody production. Previous studies revealed a similar phenotype 
when humoral responses were studied in B cell specific XBP-1-deficient mice135. 
XBP-1 is a protein involved in ER-stressed and is required for antibody-
secretion135. These data suggested that ADAM10 might regulate antibody 
production by modulating XBP-1 expression in PCs. 
 
Abnormal gene expression in plasma cells isolated from ADAM10Δ/ΔIgG1-cre+/-
YFP+ 
 Given that the phenotype observed in ADAM10Δ/ΔIgG1-cre+/-YFP+ mice 
resembled that of B cell specific XBP-1-deficient mice, we sought to determine if 
XBP-1 levels were altered in PCs isolated from ADAM10Δ/ΔIgG1-cre+/-YFP+ mice. 
Interestingly, Xbp-1 message levels were significantly reduced when compared 
to controls (Figure 36C). Studies have demonstrated that Xbp-1 expression is 
preceded by the downregulation of Bcl6 and the expression of Blimp-1 and 
IRF4135. Thus, we next looked at the expression of these genes in the 
ADAM10Δ/ΔIgG1-cre+/-YFP+ mice compared to controls. PC isolated from 
ADAM10Δ/ΔIgG1-cre+/-YFP+ mice also showed a reduction in message levels for 
Prdm1 (Figure 36A) (the gene encoding for Blmp-1) and Irf4 (Figure 36B). 
Moreover, Bcl6 levels were significantly higher than in control PCs (Figure 36D). 
Even more striking, while PC isolated from controls had ~60 fold more Prdm1 
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message than Bcl-6, PCs isolated from ADAM10Δ/ΔIgG1-cre+/-YFP+ mice showed 
only ~3 fold more Prdm1 than Bcl6 (Figure 36E). These results demonstrate that 
ADAM10 is required for the proper downregulation of Bcl-6 and upregulation of 
Prdm1, Irf4 and Xbp1, and thus for proper PC function and optimal humoral 
responses.  
Consistent with the gene expression results, flow cytometry analysis 
revealed the presence of a B220lo/-CD138+Bcl6+ population in the spleens of 
ADAM10Δ/ΔIgG1-cre+/- mice following immunization (Figure 37). These results 
demonstrate that in the absence of ADAM10, Bcl6 is overexpressed at both the 
message and protein level.   
The results are summarized in Figure 38. In the absence of ADAM10, 
there is a dysregulation in gene expression, leading to abnormal PC function and 
impaired antibody production. Further studies are needed in order to determine 
the underlying mechanisms connecting ADAM10 to Bcl6, Prdm1, Xbp1 and Irf4. 
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Figure 31. ADAM10Δ/ΔIgG1-cre+/- mice have normal germinal center 
formation.  
(A-C) Naïve mice were bled and basal antibody levels were measured by ELISA. 
(A) IgM, (B) IgG1 and (C) IgE. (D-G) Mice were immunized with NP-KLH 
emulsified in alum and 14 days post-immunization GC formation and TFH cell 
numbers were assessed by flow cytometry and immunohistochemistry. (D) 
Representative dot plot (gated on B220+ cells). (E) Quantification of GC B cells, 
representative of 5 mice from at least two independent studies. (F) Fourteen 
days after NP-KLH immunization, spleens were isolated and sectioned. Sections 
stained for GL7 (green) and IgD (red). (G) Quantification of TFH cells, 
representative of 5 mice from at least two independent studies 
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Figure 32. ADAM10Δ/ΔIgG1-cre+/- mice show impaired antibody responses to 
T-dependent antigens.  
ADAM10Δ/ΔIgG1-cre+/- (●) and controls (○) were immunized with NP-KLH 
emulsified in alum. At the indicated times, serum samples were collected and 
NP-specific (A) IgM and (B) IgG1 were measured by capture ELISA. Bars 
represent the mean ± SE of 5-9 mice per group (*p<0.05). Data represent results 
obtained in at least two independent experiments. 
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Figure 33. ADAM10Δ/ΔIgG1-cre+/- mice show impaired antibody responses to 
T-independent antigens.  
ADAM10Δ/ΔIgG1-cre+/- (●) and controls (○) were immunized with NP-LPS. At the 
indicated times, serum samples were collected and NP-specific (A) IgG3 and (B) 
IgG1 were measured by capture ELISA. Bars represent the mean ± SE of 5-9 
mice per group (*p<0.05, **p<0.01). Data represent results obtained in at least 
two independent experiments. 
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Figure 34. ADAM10Δ/ΔIgG1-cre+/- mice have normal plasma cell percentages.  
ADAM10Δ/ΔIgG1-cre+/-YFP+ and controls were immunized with NP-KLH 
emulsified in alum. Twenty-one days following immunization, tissues were 
harvested and PC numbers were analyzed. (A) Representative FACS staining of 
ADAM10Δ/ΔIgG1-cre+/-YFP+ (bottom) and controls (top).. Quantified results from 
(B) spleen, (C) peripheral blood and (D) bone marrow. Bars represent the mean 
± SE of 4-5 mice per group. Data represent results obtained in at least two 
independent experiments. 
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Figure 35. ADAM10Δ/ΔIgG1-cre+/- mice have decreased numbers of IgG1+ 
cells.   
ADAM10Δ/ΔIgG1-cre+/- and controls were immunized with NP-KLH emulsified in 
alum. Fourteen days following immunization, spleens were harvested and the 
percentage of B220+IgDloIgG1+ was quantified by flow cytometry. Quantified 
results are depicted. Bars represent the mean ± SE of 4-5 mice per group. Data 
represent results obtained in at least two independent experiments. (*p<0.05) 
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Figure 36. Plasma Cells isolated from ADAM10Δ/ΔIgG1-cre+/- have altered 
gene expression.  
ADAM10Δ/ΔIgG1-cre+/- and controls were immunized with NP-KLH emulsified in 
alum. Twenty-one days following immunization, splenic PCs were isolated via 
magnetic bead isolation. mRNA was isolated and (A) Prdm1, (B) Irf4, (C) Xbp1 
and (D) Bcl6 message levels were determined by qPCR. (E) The ratio of Prdm1 
to Bcl6 was calculated. Bars represent the mean ± SE of 3 independent studies; 
cells from 3 mice from each genotype were pooled in each study. (*p<0.05, 
**p<0.01, ***p<0.001). 
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Figure 37. Plasma cells isolated from ADAM10Δ/ΔIgG1-cre+/- mice express 
Bcl6 protein 
ADAM10Δ/ΔIgG1-cre+/- and controls were immunized with NP-KLH emulsified in 
alum. Twenty-one days following immunization, splenic plasma cells were 
analyzed by Bcl6 protein expression via flow cytometry. (A) CD138+B220lo/- B 
cells were gated and analyzed for either (B) non-specific staining (isotype) or (C) 
Bcl6 staining. (D) Quantified results are depicted. Bars represent the mean ± SE 
of 4-5 mice. (**p<0.01).  
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Figure 38. Proposed Model: Adam10 Regulations Of Plasma Cell Function   
Wild type plasma cells express much higher levels of Blimp-1, IRF4 and XBP-1 
that at previous developmental stages, while Bcl6 is repressed. This allows for 
antibody secretion. In the case of ADAM10IΔ/ΔIgG1-cre+/- mice, Bcl6 levels are 
much higher than seen in wild type. Moreover, Blimp-1, IRF4 and XBP-1 
expression are decreased, leading to impaired antibody secretion 
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3.5 Discussion 
 
 Members of the ADAM family regulate a wide range of functions, including 
cell migration, proliferation and adhesion212. ADAM10, in particular, has been 
recently shown to be critical for lymphocyte development through initiation of the 
canonical Notch signaling pathway (see Figure 3)24,174. Here we report that 
ADAM10 is dispensable for early B cell development within the bone marrow. 
However, deletion of ADAM10 from all peripheral B cells or in post-switch B cells 
leads to severe impairments in antibody responses. When ADAM10 was deleted 
from all peripheral B cells a decrease in antigen specific IgG production was 
seen both with respect to serum levels and IgG ASCs, indicating that PC 
differentiation is influenced. Cells producing high affinity antibodies were 
particularly affected, consistent with defects in GC reactions and markedly 
repressed FDC-reticula. Moreover, changes in lymphoid architecture were also 
observed. On the other hand, when ADAM10 was deleted in post-switch B cells, 
GC formation and lymphoid architecture were not impaired. Despite normal 
architecture, however, antibody production was still affected, likely due to 
abnormal gene expression in ADAM10-deficient PCs. Consistent with this 
hypothesis, PCs isolated from ADAM10Δ/ΔIgG1-cre+/- showed decreased 
expression of genes that facilitate plasma cell differentiation and function and 
increased expression of Bcl6, an inhibitor of PC differentiation. 
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ADAM10 is dispensable for early B cell development 
 ADAM10 is critical for the development of T cells due to its role in Notch1 
signaling. Studies revealed that ADAM10-deficient common lymphoid progenitor 
cells (CLPs) failed to develop into T cells, while B cell development was not 
impaired174. We decided to carry out similar experiments in order to assess 
whether ADAM10 is needed for early B cell development by knocking out 
ADAM10 in a B cell specific manner at the pro-/pre-B cell stage. Our results 
demonstrate that ADAM10 is dispensable for immature B cell development. 
Consistent with this finding, it has been recently reported that the use of an 
ADAM10 inhibitor in an in vitro system of hematopoiesis did not affect B cell 
development193.  
  
Impaired Notch signaling and increased CD23 expression are not likely to 
contribute to the phenotype observed in ADAM10B-/- mice 
 As previously mentioned, here we demonstrate that ADAM10 is essential 
for mature B cell function. ADAM10B-/- mice showed severely impaired humoral 
responses and alterations in lymphoid tissue architecture. In order to determine 
the mechanism underlying the observed phenotype, we investigated the role of 
two well described B cell expressed ADAM10 substrates: Notch and 
CD2324,174,182. The role of Notch signaling in mature B cell function is 
controversial. While some studies have clearly shown a role for Notch in antibody 
production, others failed to identify such a role177,180. In order to assess the role 
of Notch signaling in lymphoid tissue organization and antibody production, we 
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expressed N2ICD transgene in a B cell specific manner, by conditionally 
expressing N2ICD in a cre-dependent manner, under the control of CD19-cre. 
We have demonstrated that restoration of Notch2 signaling in ADAM10B-/- mice is 
not sufficient to rescue antibody production or GC formation. Studies have shown 
that N2ICD and N1ICD have redundant functions. Our results, therefore, suggest 
that the phenotype observed in ADAM10B-/- mice is not dependent Notch1 nor 
Notch2 signaling213, however, whether impaired Notch1 signaling contributes to 
the phenotype observed in ADAM10B-/- mice should be formally studied.  
 Another feature of ADAM10-deficient B cells is decreased expression of 
CD2124. Since Notch signaling enhances CD21 expression, the finding that the 
introduction of the N2ICD transgene failed to rescue antibody production and GC 
formation in ADAM10B-/- mice also suggests that CD21 is not involved in the 
ADAM10B-/- phenotype, N2ICD transgene expression led to increase CD21 
expression. In addition, unlike CD21/CD35-/- mice, ADAM10B-/- mice had impaired 
affinity maturation and failed to mount antibody responses comparable to 
controls following immunization even at large antigen dosages (i.e. 1mg)214. 
 CD23, also known as the low affinity IgE receptor, is another B cell 
expressed ADAM10 substrate182. We have recently demonstrated that CD23 
surface expression is significantly enhanced after deletion of ADAM10 in B 
cells24. Defects observed in ADAM10B-/- could result from CD23 overexpression. 
Previous studies with CD23Tg mice, however, demonstrated that elevated CD23 
levels resulted in inhibition of IgE and IgG1 production, while other classes were 
not significantly affected. On the other hand, in ADAM10B-/- mice, the production 
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of all classes of IgG was impaired. Moreover, when immunized with NP-KLH, 
CD23Tg mice had Ig levels comparable to that of WT. In contrast, ADAM10B-/- 
mice showed diminished levels of both low and high affinity anti-NP antibodies. 
These results suggest that elevated CD23 levels do not explain the phenotype of 
ADAM10B-/- mice. However, in order to demonstrate that the phenotype observed 
in ADAM10B-/- mice is CD23-independent, we are generating mice that lack both 
CD23 and B cell expressed ADAM10 by mating CD23-/- mice and ADAM10B-/- 
mice215 It is possible that another B cell expressed ADAM10 substrate is 
responsible for the phenotype observed in ADAM10B-/- mice.  
 
ADAM10 is important for B cell follicle formation and maintenance of lymphoid 
architecture  
 In lymphoid organs, the correct positioning of B cells and T cells as well as 
the migration during an immune response are critical for adequate interaction 
between them28. As previously mentioned, interactions between cognate B cells 
and T cells play are essential for adequate responses to T-dependent antigens. 
Our results demonstrate that while B cell expressed ADAM10 is dispensable for 
B cell homing during LN and spleen development, ADAM10 is critical for the 
maintenance of B cell and T cell positioning subsequent to immune stimulation. 
However, ADAM10 also is needed for normal B cell follicle formation, as a 
thinning of B cell follicular areas was observed in LN of ADAM10B-/- mice. The 
aberrant B cell follicle structure is accompanied with excessive collagen 
deposition and a relative increase in FRCs.  
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 TNF-α is another ADAM10 substrate and it has been implicated in the 
formation of primary B cell follicles and GCs185. Unlike ADAM10B-/- mice, TNF-α 
deficient mice have a more dramatic disruption of splenic architecture prior to 
immunization14. However, TNF-α deficient or TNF-α receptor-deficient mice also 
had normal B cell homing but defective B cell follicle formation216,217. Moreover, 
studies have demonstrated that secreted TNF-α is important for lymph node 
architecture, while membrane bound TNF-α is sufficient to support normal splenic 
architecture development217. Furthermore, B cells were found to be an essential 
source of secreted TNF-α during LN development202. Interestingly, despite 
normal TNF-α expression, ADAM10-deficient B cells secreted significantly less 
TNF-α than WT B cells following in vitro stimulation. These results suggest that 
the abnormal appearance of B cell follicles in LN of ADAM10B-/- is likely due to a 
defect in B cell TNF-α shedding.  
 Lymphotoxin-alpha (LT) is another TNF-α family member that is involved 
in lymphoid architecture. The phenotype of ADAM10B-/- mice is also different to 
that seen with LT-deficient mice, however, as LT-deficient mice lack peripheral 
LN and have severely disrupted splenic architecture12. Interestingly, LT has been 
shown to be important for the maintenance of splenic architecture in adult 
mice218. These results suggest that during an active immunization, lymphotoxin 
production by ADAM10-deficient B cells might be impaired.  
 CCL21, CCL19 and CXCL13 have been shown to play a key role in 
inducing and maintaining normal cellular compartments18. Draining LNs from 
ADAM10B-/- mice showed increased CCL21 mRNA expression. This increase in 
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CCL21 was also confirmed at the protein level by immunohistochemistry. 
Interestingly, ADAM10B-/- mice had a larger area of CCL21 staining, consistent 
with the aberrant T cell localization seen in draining LNs. The cells responsible 
for CCL21 production in LN are fibroblastic reticular cells (FRCs)219,220. Despite 
having normal CCL21 mRNA levels, compared to WT LN, FRCs made up a 
larger percentage of the stromal cells present in LN of ADAM10B-/- mice. Recent 
studies have demonstrated that following immunization, FRCs expand in a B cell 
dependent manner. Therefore, it is likely that due to the basal increase in FRCs 
observed in ADAM10B-/- LN, an increase in CCL21 is also apparent. FRC 
numbers following immunization should be studied in ADAM10B-/- mice.  
 FDCs are important for GC development, CSR, SHM and affinity 
maturation as well as induction of recall responses105,221-225. FDCs also secrete 
CXCL13 and are thus important for recruitment of CXCR5-expressing B cells and 
T cells into the follicle226. Moreover, they are required for the maintenance of B 
cell and T cell zones28. The loss of B cell and T cell segregation and the lack of 
GCs in the draining secondary lymphoid tissues of ADAM10B-/- mice are thus 
consistent with a decreased number of FDC networks. The fact that CXCL13 
mRNA levels were not altered, despite the lack of FDCs was surprising. 
However, recent published reports have also noted that CXCL13 expression is 
not affected by FDC depletion227. Together, these results challenge that idea that 
FDCs are the main producer of CXCL13.  
 Studies have demonstrated that FDCs are required for GC B selection 
within GCs. If GC B cells fail to interact with immune complexes displayed in the 
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surface of FDCs, the cells will undergo apoptosis96. FDC-mediated GC B cell 
selection is consistent with the finding that in the absence of FDCs GC B cell 
numbers are diminished, as observed in ADAM10B-/- mice. 
 The changes in architecture correlate with the decrease in TFH cells. TFH 
cells provide B cell help and are thus essential for PC differentiation, memory cell 
generation and affinity maturation228. A decrease in the number of TFH cells leads 
to decreased B cells help, thus leading to diminished isotype switching.   
ADAM10 might regulate B cell activation 
 Decreased B cell activation is consistent with the phenotype we observe in 
the ADAM10B-/- mice and it is the likely to contribute to the defect in humoral 
responses. When B cells were stimulated with LPS, ADAM10-deficient B cells 
showed impaired antibody productions. However, when ADAM10-deficient B 
cells were stimulated with anti-CD40 and IL-4, antibody production was not 
affected. These results suggest that ADAM10 might be involved in B cell 
activation, but its involvement might dependent on the specific stimulation. B cell 
activation in vitro occurs very differently from antigen-specific in vivo responses, 
thus making it difficult to correlate in vitro and in vivo findings. Discrepancies 
between in vivo and in vitro results might relate to differences in short lived and 
long-lived plasma cells.  Moreover, in vitro differentiation assays often lead to a 
heterogenous population of cells, displaying different degrees of activation thus 
making the study of B cell responses difficult. Furthermore, in vitro activation 
might not precisely reflect in vivo stimulation 229.  
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ADAM10 is required for plasma cell function 
 The changes in architecture observed in ADAM10B-/- mice did not allow us 
to discern whether ADAM10 is important for antibody production or if the defects 
in antibody responses were secondary to architectural changes. Here we 
demonstrate that mice with ADAM10–deletion in class-switched B cells 
(ADAM10Δ/ΔIgG1-cre+/- mice) have normal GC formation and show no changes in 
lymphoid architecture. These mice, however, showed defective antibody 
responses to T-dependent and T-independent antigens. Furthermore, we show 
that despite having normal PC percentages, defined as CD138-expressing cells, 
expression levels of transcription factors important for PC development, Prdm1, 
xbp1 and Irf4 were altered, while housekeeping gene levels remained 
unchanged.  In addition, the GC transcription factor Bcl6 was not properly 
downregulated in ADAM10Δ/ΔIgG1cre+/- mice. These results demonstrate that 
ADAM10 is required for proper downregulation of Bcl6, upregulation of Prdm1, 
Irf4 and Xbp1. Subsequently, antibody secretion is abnormal in 
ADAM10fl/flIgG1cre+/- mice. Thus ADAM10 is important for proper PC function in 
vivo. Interestingly, when gene expression was assessed in in vitro activated B 
cells, gene expression varied from sample to sample, thus making it difficult to 
discern differences between WT and ADAM10-deficient B cells. These results 
are consistent with the concept that in vitro activation leads to heterogenous 
populations of cells229. 
 The transcription factor Bcl6 is necessary for GC formation and B cell 
proliferation. While it is well established that Bcl6 must be downregulated for PC 
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differentiation to occur230, the factors mediating its downregulation are not fully 
understood. It has been previously demonstrated that STAT3, downstream of IL-
21, can trigger Blimp-1 expression by competing with Bcl6 for DNA binding 
sites109. Moreover, it has been proposed that B-cell receptor (BCR) and CD40 
signaling lead to Bcl-6 degradation110. Recent studies demonstrated that ectopic 
STAT3 signaling could induce Blimp-1 expression even in the presence of high 
Bcl-6 levels; however, PC differentiation did not proceed until Bcl6 levels were 
reduced109. Here we demonstrate that ADAM10 is essential for Bcl6 
downregulation at least in vitro and that ADAM10 deficiency leads to impaired 
antibody responses. 
 Studies have demonstrated that IL-6 signaling can induce Bcl6 
expression99,103. In the context of a GC, IL-6 is produced by activated FDCs and 
promotes SHM and affinity maturation105. Given that ADAM10 is responsible for 
the cleavage of the IL-6 receptor  (IL-6R)183, one could speculate that increased 
IL-6R expression could lead to increased IL-6 signaling, thus leading to Bcl6 
overexpression.  
 Along with defective Bcl-6 downregulation observed in PCs isolated from 
ADAM10B-/- mice, ADAM10 deletion also resulted in decreased levels of Prdm1, 
the gene encoding for Blimp-1, Irf4 and Xbp-1. Blimp-1 and IRF4 lead to cell 
cycle arrest and promote PC development133, while XBP-1 is required to for 
endoplasmic reticulum (ER) expansion and immunoglobulin production and 
secretion134 Moreover, Blimp-1 and IRF4 permit XPB1 expression132,134. 
Furthermore, it has been very well documented that Bcl-6 can inhibit Blimp-171. It 
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is therefore possible that ADAM10 is involved in a pathway that controls both 
Blimp-1 and IRF4 expression, and decreased Blimp-1 and IRF4 then leads to 
decreased XBP-1 expression.   
 As demonstrated in this study, humoral responses were severely impaired 
in ADAMΔ/ΔIgG1-cre+/- mice. Surprisingly, the number of PCs was comparable 
between ADAMΔ/ΔIgG1-cre+/- mice and controls. Previous studies revealed a 
similar phenotype when humoral responses were assessed in B cell specific 
XBP-1-deficient mice. As previously mentioned, XBP-1 is a transcription factor 
involved in ER-stressed and is required for antibody-secretion. PCs isolated from 
ADAMΔ/ΔIgG1-cre+/- mice had decreased XBP-1 message levels, suggesting that 
the phenotype observed in ADAMΔ/ΔIgG1-cre+/- mice is partly due to decrease 
XBP-1 expression and impaired antibody secretion.  
 As previously mentioned, ADAM10 is critical for Notch1 and Notch2 
cleavage and the initiation of the canonical Notch signaling pathway (see Figure 
2)24,174. The role of Notch signaling in GC formation and PC differentiation, 
however, remains controversial. In vivo studies of B cell specific RBP-Jk-deficient 
mice, a key mediator of Notch signaling, failed to reveal a defect in antibody 
production180. Consistent with this finding, a recently published report 
demonstrated that B cell-specific Notch2-deficient mice have normal GC 
formation231. Moreover, mice with constitutively active Notch2 intracellular 
domain (Notch2-ICD) showed defective antibody responses to T-dependent and 
T-independent antigens and impaired GC formation232. On the other hand, in 
vitro studies have demonstrated that Notch signaling enhances B cell activation 
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and supports B cell survival178. Moreover, recent studies have shown that Notch 
signaling synergizes with B-cell receptor (BCR) and CD40 signaling to enhance 
murine B cell activation177. Further studies will be needed to elucidate the role of 
Notch1 and Notch2 in PC differentiation and function and to determine whether 
the phenotype observed in ADAMΔ/ΔIgG1-cre+/- mice results from defective Notch 
signaling.   
  
ADAM10: Not just a sheddase 
 Cleavage of membrane-bound proteins, such as Notch receptors, is not 
the only way that ADAM10 is capable of modulating gene expression. Recent 
experiments have demonstrated that ADAM10 not only mediates receptor 
intramembrane proteolysis (RIP), but it is also subject to RIP. ADAM9 and 
ADAM15 have been identified as the proteases responsible for releasing the 
ADAM10 ectodomain, while gamma-secretase mediates the release of the 
ADAM10 intracellular domain (ICD). ADAM10-ICD then translocates to the 
nucleus and modulates gene expression162. Studies have demonstrated that 
nuclear ADAM10 can interact with androgen receptors and act like a transcription 
factor233. It is thus possible that ADAM10 regulates Bcl-6 expression and PC 
function, not by shedding of membrane proteins but through its involvement in 
gene regulation. These recent findings really expand the potential roles for 
ADAM10 in regulating cellular functions. ADAM10-ICD regulation of gene 
expression will require further study.   
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 Several reports have demonstrated that ADAM10 and a few of its 
substrates are present in exosomes, which are small secreted vesicles159,160. It is 
possible that ADAM10-expressing B cell secreted exosomes play a role in 
regulating GC formation and PC differentiation. However, further experiments are 
necessary to determine the mechanism by which B cell expressed ADAM10 
controls humoral responses, lymph node development and the maintenance of 
lymphoid architecture.  
  
Conclusions and future directions 
 In conclusion, while ADAM10 is dispensable for early B cell development, 
our studies have demonstrated that ADAM10 is critical for the maintenance of 
splenic and lymph node architecture during active immune responses. ADAM10-
deletion from all peripheral B cells (ADAM10B-/- mice) led to decreased numbers 
of TFH cells, leading to diminished T cell help and impaired GC formation, affinity 
maturation and CSR. On the other hand, deletion of ADAM10 in GC B cells does 
not impair GC formation. However, despite normal PC numbers, 
ADAM10Δ/ΔIgG1-cre+/-YFP+ mice showed impaired antibody responses to T-
dependent and T-independent antigens. Gene expression analysis demonstrated 
that PCs isolated from ADAM10Δ/ΔIgG1-cre+/-YFP+ mice expressed lower levels 
of Prdm-1, Irf4 and Xbp-1 and expressed 3-fold more Bcl6 than WT counterparts. 
These results thus demonstrate that ADAM10 is important for PC function, 
independently of the changes in architecture observed in ADAM10B-/- mice.  
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 While the studies described here have really expanded our knowledge of 
the role of B-cell expressed ADAM10 in B cell biology and the development and 
maintenance of lymphoid tissue architecture, there are many questions that have 
not been addressed. While we know that ADAM10-mediates B cell follicle 
formation, likely through TNF-α shedding, this has not been proven. Mixed bone 
marrow chimera with WT and ADAM10B-/- BM and ADAM10B-/- and TNF-α-/- BM 
will be used to determine whether impaired TNF-α release in ADAM10B-/- mice 
results in impaired B cell follicle formation. While LN from WT/ADAM10B-/- mice 
should be normal because WT B cells can provide enough TNF-α-/- to allow for 
normal B cell follicle formation, we would expect that LN from ADAM10B-/-/ TNF-α-
/- would have impaired follicle formation, as ADAM10-deficient B cells nor TNF-α-
deficient B cells could release TNF-α and support B cell follicle formation.  
 The work described here focuses on the role of ADAM10 in conventional 
or B2 B cells. Another B cell subset are B1 B cells. B1 B cells are located mostly 
within the peritoneal cavity and produce natural antibodies. Natural antibodies 
are antibodies that recognize very common bacterial antigens, such as 
phosphorycholine234. It would be interesting to determine whether ADAM10 also 
plays a role in B1 B cell function.  
 Secondary lymphoid organs are positioned such that they facilitate 
immune responses to foreign antigens. In states of chronic inflammation, 
lymphoid cell aggregates that have a similar organization to secondary lymphoid 
organs can develop; these structures are known as tertiary lymphoid structures. 
These structures have been described in patients with atherosclerosis and 
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rheumatoid arthritis28. Tertiary lymphoid organs have organized B cell 
compartments, which often include GCs, and T cell compartments, in which 
antigen-presenting cells can be detected. When tertiary organs develop at sites 
where autoantigens are continuously being presented, they may lead to 
unnecessary tissue destruction by facilitating the activation of autoreactive 
lymphocytes28. Our results demonstrate that ADAM10 is critical for the structural 
maintenance of secondary lymphoid organs during active immune responses and 
thus, suggest a role for ADAM10 in the maintenance of tertiary lymphoid organs. 
Further experiments are needed to determine whether ADAM10 plays a role in 
tertiary lymphoid tissue formation and whether ADAM10 is a potential therapeutic 
target for the treatment of diseases involving tertiary lymphoid tissues. As 
complete loss of ADAM10 is lethal in utero158, systemic ADAM10 blockade could 
have severe side effects.  We have recently shown that intranasal administration 
of ADAM10 inhibitors reduced symptomology in the mouse asthma model 
without causing any obvious deleterious effects235. Thus, it may be possible to 
use local ADAM10 inhibition in some B-cell mediated autoimmune scenarios to 
decrease autoimmune symptoms. ADAM10 inhibition is not only likely to affect 
tertiary lymphoid structure, but also to affect autoantibody production within these 
tissues. 
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CHAPTER 4: FYN IS REQUIRED FOR OPTIMAL GERMINAL CENTER 
FORMATION AND ANTIBODY PRODUCTION  
4.1 Introduction to Fyn 
 The gene SH2D1A encodes for SLAM-associated protein (SAP). 
Mutations in this gene resulting in SAP-deficiency or SAP protein destabilization 
cause X-linked lymphoproliferative disease (XLP). Patients with XLP often have 
difficulties clearing infections, such as EBV, measles virus and Neisseria 
meningitides. They also show progressive hypogammaglobulinemia and 
increased incidence of B cell lymphomas236. 
 SAP interacts with SLAM (CD150) through binding to the cytoplasmic tail. 
Subsequently, SAP recruits the Src protein kinase Fyn. Studies have 
demonstrated that SAP directly binds Fyn via an unconventional SH3 domain-
binding surface237-239. This binding requires arginine 78 residue (R78) on the SAP 
protein237,239. Recruitment of Fyn leads to the phosphorylation of tyrosine 
residues in the cytoplasmic domain of SLAM. This phosphorylation event 
generates docking sites for several proteins and initiates signaling cascades240.  
 Fyn is a member of the Src protein tyrosine kinase. Fyn is widely 
expressed in many cell types, including lymphocytes241. Fyn has been shown to 
interact with both the B cell and T cell receptor (BCR and TCR, 
respectively)242,243. While Fyn-deletion did not impair the development of 
immature T cells and B cells, TCR signaling was altered in mature T cells143,244.  
 Recent studies have suggested that SAP regulates NKT cell development 
in a Fyn-dependent and independent manner. Experiments demonstrated that 
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SAP-deficient mice have a reduction in the number of NKT cells. Mice expressing 
SAP R78A, a mutant SAP that is unable to bind Fyn (SAPR78A mice), still had 
diminished NKT cell numbers, but the defect in NKT cell development was not as 
pronounced as that observed in SAP-deficient mice245.  
 Another feature of SAP-deficient mice is a severe impairment in GC 
development accompanied with impaired generation of memory B cells and long-
lived plasma cells246. Through the use of conditional SAP-knockouts and 
adoptive transfer approaches, two groups demonstrated that T cell SAP 
expression was important for humoral responses67,246. B cell specific SAP 
deficiency did not impair antigen-specific immunoglobulin production or GC 
formation. Indeed, GC B cell numbers were enhanced in SAPΔ/ΔCD19-cre+ 
mice67. Further studies demonstrated that SAP was dispensable for the 
interaction between T cells and DCs. However, SAP-deficient T cells were shown 
to be unable to make stable interactions with cognate B cells66. It was later 
determined that these defects in stable B-T interactions resulted in impaired TFH 
development and diminished T cell help247,248.  
 Interestingly, it was demonstrated that SAP regulates TFH development in 
a Fyn-independent manner, as evidenced by the fact that SAPR78A mice had 
normal TFH and GC B cell numbers247,249. Experiments with Fyn-deficient mice 
(Fyn-KO) demonstrated that they are able to form GCs. The authors of these 
studies concluded that Fyn is dispensable for GC formation, however,  how GC B 
cell numbers compare to that of wild type cannot be deduce from thes studies 
being that Fyn-KO mice are in a B6.129 background and no B6.129 wild type 
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mice were studied in those experiments249. 
 The SAP-Fyn axis has also been demonstrated to mediate many aspects 
of T cell biology. Studies have demonstrated that both Fyn and SAP are 
important for Th2 differentiation. Studies have demonstrated that Fyn-KO and 
SAP-deficient T cells produced little to no IL-4 following anti-CD3 and anti-CD28 
stimulation250. Moreover, it has been reported that TFH cells present within GCs 
(GC TFH cells) depend on the SAP-Fyn axis for IL-4 production248.  
 The data regarding the role of Fyn in cytokine production and Th2 cell 
differentiation is conflicting. While some have reported that Fyn-KO mice are 
impaired in IL-4 production250, other have reported that Fyn-KO T cells 
preferentially differentiate into Th2 cells251. Furthermore, it was reported that Fyn-
KO T cells produced increased levels of IL-4 but reduced IFN-γ levels251,252. 
Consistent with these findings, Fyn-KO T cells showed exaggerated responses in 
a mouse model of allergic airway inflammation253. Interestingly, while naïve Fyn-
deficient mice had reduced IgE levels, immunized mice had comparable IgE 
levels to that of WT253. Others have demonstrated that Fyn-KO mice have 
elevated IgE following immunization254. It is possible that Fyn is involved in the 
secretion of both IL-4 and IFN-γ and which cytokine is more impaired might 
depend on the situation.  
 While much of the research regarding Fyn in lymphocyte biology has 
focused on T cells, Fyn is also expressed in B cells255. As previously mentioned, 
Fyn interacts with the BCR. Moreover, Fyn interacts with the BCR co-receptor 
CD19 (See Chapter 1)256. Interestingly, Fyn-KO B cells showed only a mild 
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impairment in BCR signaling257. Moreover, humoral responses to T-dependent 
antigens 7 days following immunization were lowered in Fyn-KO mice, although 
the difference was not statistically significant, likely due to the fact that only few 
mice per group were used in these experiments257. On the other hand, Fyn-KO 
mice showed a marked decrease in Ig subsequent to T-independent 
antigens244,258. 
 Fyn has also been associated with IL-5 receptor142,257. IL-5 is a pleotropic 
cytokine. With regard to B cells, IL-5 signaling has been shown to contribute to 
induce IgA production by antigen-primed B cells and LPS stimulated B 
cells259,260. Moreover, in the presence of IL-4, IL-5 can induce IgG1 and IgE 
secretion. It has been demonstrated that in combination with IL-4, IL-5 leads to 
the accumulation of γ1 and ε chain transcripts261. Fyn-KO B cells have been 
shown to have impaired IL-5 signaling142. 
 Fyn has also been shown to associate with CD23, the low affinity IgE 
receptor, also known as FcεRII. Studies of CD23-deficient and CD23-transgenic 
mice demonstrated that CD23 is the natural regulator of IgE production262. The 
role of Fyn in CD23 signaling and IgE production should be carefully assessed. 
 While a role for Fyn in cytokine production and antibody responses has 
been reported, the role of Fyn in humoral responses remains controversial. We 
thus decided to examine humoral responses in Fyn-KO mice. Our results 
demonstrate that Fyn-KO mice have significantly low basal IgG1 and IgG2a. 
Additionally, these mice displayed delayed kinetics in the production of NP-
specific IgG1 and IgG2b, and significantly low NP-specific IgG2a after a T-
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dependent immunization protocol. Defects in antibody production correlated with 
significantly reduced numbers of GC B cells, TFH cells and spleen plasma cells. 
Moreover, Fyn-KO B cells showed decreased antibody production following in 
vitro activation. Our results thus demonstrate that Fyn-mediated signaling is 
necessary for optimal humoral responses. 
 
4.2 Results 
Fyn deficient animals have low basal IgG1 and IgG2a 
 In order to better understand Fyn’s role in humoral immunity, we analyzed 
antibody levels in the serum of naïve Fyn-KO and WT B6.129 mice. Compared to 
WT, Fyn-KO mice had normal IgM levels and IgG2b, but significantly decreased 
basal IgG1 levels and IgG2a (Figure 39). IgE levels were below the levels of 
detection in both WT and Fyn-KO mice. These findings implicated Fyn in 
antibody production. 
 
Fyn kinase deficiency affects antigen-specific antibody production 
 To directly assess antigen-specific antibody production, Fyn-KO and WT 
mice were immunize i.p. with NP-KLH in alum and the generation of NP-specific 
antibodies was monitored by ELISA. Surprisingly, while Fyn-KO mice showed 
normal antigen-specific IgM responses (Figure 40A), they had a severely 
impaired NP-specific IgG2a response (Figure 40C). With regards to NP-specific 
IgG1 and IgG2b, Fyn-KO mice demonstrated a delayed in Ig production, but had 
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normal levels of NP-specific Ig four weeks following immunization (Figure 
40B,D), suggesting abnormal antibody production kinetics. 
 
Splenic PC numbers are reduced in Fyn deficient mice 
 Given the diminished antibody response observed in Fyn-KO mice, we 
hypothesized that CSR or PC development were impaired in these mice. In order 
to determine whether PC generation was abnormal in Fyn-KO mice, we 
immunized mice with NP-KLH and determined the number of PC by flow 
cytometry 14 days post-immunization. Consistent with the defects in antibody 
production, Fyn-KO mice showed decreased in the proportion of splenic PCs 
(CD138+B220lo/- cells) (Figure 41).  
 
GC formation is impaired in Fyn deficient mice 
 A large portion of PCs in response to T-dependent antigens are derived 
from GCs, we therefore assessed GC formation in Fyn-KO mice. GC B cells, 
defined as B220+GL7+Fashi were enumerated by flow cytometry 14 days 
following NP-KLH immunization. Our results demonstrate that 14 days post-
immunization, Fyn-KO mice showed significantly decreased levels of GC B cells 
compared to WT controls (Figure 42). 
  
TFH formation is impaired in Fyn deficient mice 
 TFH cells provide B cell help via CD40L, IL-21 and IL-4. They play a key 
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role in GC B cells survival, affinity maturation, and plasma cell differentiation. TFH 
cells are characterized by high expression of CXCR5 and programmed death-1 
(PD-1). We therefore examined whether the decreased number on GC B cells 
was accompanied with decrease TFH number. TFH cells were enumerated by flow 
cytometry 14 days following NP-KLH immunization. Interestingly, TFH numbers 
were significantly reduced in Fyn-KO mice (Figure 43). Our data reveal a novel 
role of Fyn kinase. Our experiments demonstrate that Fyn is required for optimal 
GC B cell and TFH cell development or maintenance. 
 
Fyn kinase is required for B cell antibody production in vitro 
 In order to determine whether Fyn-deletion affected antibody production in 
a B cell intrinsic manner, WT and Fyn-KO B cells were stimulated with anti-CD40 
and IL-4. Proliferation and antibody production were then measured. Compared 
to WT B cells, Fyn-KO B cells produced significantly lower amounts of IgG1 and 
IgE (Figure 44A,B). These results demonstrate that, at least in vitro, Fyn-KOB 
cells have impaired activation. Interestingly, Fyn-KO B cells showed no alteration 
in proliferation (Figure 44C). It is likely that the phenotype observed in vivo 
results from both a B cell-intrinsic defect and impaired cytokine production. 
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Figure 39. Fyn deficient mice have impaired humoral responses.  
Serum  (A) IgM, (B) IgG1, (C) IgG2a and (D)IgG2b were measured by ELISA 
from non-manipulated 8-12 week old mice. Bars represent the mean ± SE of 10 
mice per group (***p<0.001). Data represent results obtained in at least two 
independent experiments. 
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Figure 40. Fyn-KO mice have impaired humoral responses to T-dependent 
antigens 
Fyn-KO mice and WT controls were immunized with 10µg NP-KLH emulsified in 
alum. At the indicated times, serum samples were collected and NP-specific (A) 
IgM, (B) IgG1, (C) IgG2a and (D) IgG2b antibody titers were determined by 
ELISA. Bars represent the mean ± SE of 5-9 mice per group (*p < 0.05, **p<0.01, 
***p<0.001). Data represent results obtained in at least two independent 
experiments. 
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Figure 41. Fyn-KO mice have reduced plasma cell percentages.  
Fyn-KO and WT mice were immunized with NP-KLH emulsified in alum. Twenty-
one days following immunization, spleens were harvested and PC numbers were 
analyzed. (A) Representative FACS staining. (B) Quantified results from spleen. 
Bars represent the mean ± SE of 6 mice per group. Data represent results 
obtained in at least two independent experiments. (p<0.01) 
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Figure 42. Fyn deficient mice have impaired germinal center formation.  
Mice were immunized with NP-KLH emulsified in alum and 14 days post-
immunization GC formation was assessed by flow cytometry. (A) Representative 
dot plot (gated on B220+ cells). (B) Quantification of GC B cells. Bars represent 
the mean ± SE of 6 mice per group. Data represent results obtained in at least 
two independent experiments. (p<0.001) 
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Figure 43. Fyn deficient mice have reduced TFH numbers 
Mice were immunized with NP-KLH emulsified in alum and 14 days post-
immunization TFH cell numbers were assessed by flow cytometry. (A) 
Representative dot plot (gated on CD4+ cells) (B) Quantification of TFH cells. Bars 
represent the mean ± SE of 6 mice per group. Data represent results obtained in 
at least two independent experiments. (p<0.001). 
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Figure 44. Fyn deficient B cells produce reduced antibody levels despite 
normal proliferation following in vitro stimulation. 
B cells were isolated and cultured with IL-4 and anti-CD40L. Eight days following 
stimulation, supernatant were harvest and analyzed for (A) IgG1 and (B) IgE by 
ELISA. (C) Three days following challenge, tritiated thymidine was added to cells. 
Cells were incubated for 24 hours and then harvested. Thymidine incorporation 
was then measured. Experiment has been performed three times with similar 
results. (*p<0.05, **p<0.01). 
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4.3 Discussion 
 Fyn is a member of the Src protein tyrosine kinase family. Previous work 
has demonstrated that Fyn-deficient T cells have impaired cytokine production 
that is accompanied by impaired antibody production. However, several 
conflicting reports have been published. Here we demonstrate that Fyn-KO mice 
showed decreased basal IgG1 and IgG2a levels. Additionally, following 
immunization, these mice had altered kinetics regarding NP-specific IgG1 and 
IgG2b productions. Moreover, Fyn-deficient mice displayed a dramatic defect in 
NP-specific IgG2a production. These defects correlated with significantly reduced 
numbers of GC B cells, TFH cells and spleen PCs. Moreover, Fyn-KO B cells 
showed decreased antibody production following in vitro activation. Our results 
thus demonstrate that Fyn-mediated signaling is necessary for optimal humoral 
responses. 
 The role of Fyn in GC formation has been previously assessed. Cannons, 
et al. immunized C57B6 WT, 129 WT mice and Fyn-KO mice in a mixed 
C57B6.129 background. In these experiments, C57B6 WT mice had fewer GC B 
cells than 129 WT mice, while Fyn-KO mice had GC B cell numbers comparable 
to C57B6 WT mice. Based on these results, the authors concluded that Fyn was 
dispensable for GC formation249. However, it is difficult to draw conclusions form 
these experiments given that the mice were not background matched. Our 
results demonstrate that Fyn is important for GC B cell differentiation.  
 It has been previously reported that Fyn is involved in IL-4 secretion. 
While some report that Fyn-deficient T cells are unable to secrete IL-4, others 
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demonstrate that Fyn-deficient T cells are skewed toward a Th2 phenotype, 
results in increased IL-4 production and decreased IFNγ250,251,254,263. These 
cytokines promote the production of different Ig isotypes. While IL-4 promotes 
IgG1 and IgE class switching, IFNγ induces IgG2a production40-42,80.Here we 
demonstrate that Fyn-KO mice have dramatically reduced basal and antigen-
specific IgG2a levels. These results are consistent with the notion that IFNγ 
production is impaired in Fyn-KO mice.  
 We also noted that Fyn-KO mice have a delayed kinetics in the production 
of antigen-specific IgG1 and IgG2b. Moreover, these mice had fewer numbers of 
GC B cells following immunization. IL-4 has been implicated in GC formation. 
Indeed, IL-4-deficient mice have smaller GCs than WT mice264.Given the fact that 
Fyn is important for IL-4 production, it is possible that reduced IL-4 leads to fewer 
GC B cells resulting in impaired Ig kinetics.   
 Along with defective GC formation, we noticed a decrease in splenic PCs 
and TFH cells. It is likely that they are both secondary to the decrease in GC B 
cells. Previous work demonstrated that SAP-Fyn interactions were dispensable 
for TFH development, as TFH cells developed normally in SAPR78A mice249. 
Therefore, our results suggest that Fyn regulated TFH differentiation in a SAP-
independent manner.  
 Given that Fyn is involved cytokine production, it is hard to delineate 
whether the defects in immunoglobulin production observed result from B cell 
intrinsic defects or if they are due to altered cytokine production. However, the 
fact that Fyn-deficient B cells had impaired antibody production in vitro indicates 
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that Fyn plays a role in B cell activation. Interestingly, Fyn-deficient B cells 
proliferated normally, suggesting a role for Fyn in antibody class switching.  
 Future studies will be needed to identify the mechanism underlying the 
defects in humoral responses in Fyn-deficient mice. While our in vitro studies 
demonstrate a B cell intrinsic defect, we have not demonstrated a B cell defect in 
vivo. In order to identify whether the phenotype observed results from Fyn-
deficiency in B cells or T cells, mice that lack lymphocytes (RAG2-/- mice) will be 
reconstituted with a combination of WT B cells and Fyn-deficient T cells or vice 
versa. These mice will then be immunized and antibody responses will be 
assessed. It is likely that both B cell and T cell-expressed Fyn play a role in 
humoral responses.   
 Fyn-deficient mice have been studied extensively. It has been 
demonstrated that Fyn kinase is required for NKT cell development245. Moreover, 
it has been demonstrated that Fyn is also involved in T cell activation and 
cytokine production143,242,254. Moreover, some studies have demonstrated that 
Fyn is important for antibody production in vivo, although others failed to identify 
such role252,254,265. Our results further extend our knowledge of Fyn’s role in 
lymphocyte biology. Here we demonstrate that Fyn is important for optimal 
humoral responses by regulating GC formation and possibly CSR. Moreover, our 
data show that Fyn mediates antibody production via B cell intrinsic and extrinsic 
manners.   
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